Thromboxane receptor antagonists

ABSTRACT

The invention generally relates to compounds that function as TP antagonists for treating thrombosis and other cardiovascular, renal, or pulmonary diseases. In some embodiments, the invention provides a compound including a substituted nitro phenoxy phenyl, a sulfonylurea, and an alkyl group. In some embodiments, the invention provides a method of treating thrombosis by administering an antithrombotic compound that preferentially binds to a thromboxane receptor, has preferential binding for either TPalpha (TPα) or TPbeta (TPβ) receptor subtype.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims priority to, and the benefit of, U.S.Provisional Application Nos. 61/625,540, 61/625,537, and 61/625,516,each of which were filed Apr. 17, 2012, the contents of each of whichare incorporated by reference herein in their entirety.

FIELD OF THE INVENTION

The invention generally relates to compounds that function as TPantagonists for treating thrombosis.

BACKGROUND

Blood clotting is an important mechanism in preventing blood loss inresponse to blood vessel injury. Sometimes, however, clotting occurs inthe blood vessels of a healthy person in a process called thrombosis.The resulting blood clot, or thrombus, is largely composed of blood cellfragments known as platelets or thrombocytes. A thrombus that dislodgesand circulates within the blood (“embolizes”) is known as an embolus.

Thrombosis and embolism are associated with many cardiovasculardiseases. When thrombosis blocks the normal flow of blood in arteries, adecreased supply of oxygen and glucose can cause tissue damage. Therestricted blood flow, or ischemia, can cause injury to any organ andmay even result in death. When a thrombus disturbs the supply of bloodto the brain, a stroke may result. When a thrombus obstructs a coronaryartery, the result can be a heart attack. Other diseases associated withthrombosis include angina pectoris, transient ischemic attack,peripheral arterial disease (PAD), peripheral vascular disease (PVD) andarterial thrombosis, to name a few. Accordingly, there is medicalinterest in treating thrombosis.

Thrombosis is stimulated by the arachidonic acid-derived prostanoidthromboxane (TX) A₂. TXA₂ triggers platelet activation and aggregationby agonistically binding to receptors on the surface of platelets andstimulating the expression of integrins on the platelet surface.Integrins on one platelet are then bound by fibrinogen to otherplatelets, thereby building up a clot. TXA₂ also stimulates contractionof various types of smooth muscle including vascular smooth muscle,leading to vasoconstriction, as well as of renal and pulmonary smoothmuscle.

Attempts to treat thrombosis have involved targeting the synthesis ofTXA₂. An enzyme called cyclooxygenase (COX) produces prostaglandin (PG)H₂ through its enzymatic conversion from the 20 carbon lipid arachidonicacid to generate a series of lipid mediators referred to as theprostanoids. In this synthetic pathway, the COX-derived PGH₂endoperoxide product is converted by a host of specific PG synthases tomake the prostaglandins PGD₂, PGE₂, PGF_(2α), and PGI₂ (Prostacyclin)and by TXA synthase to make TXA₂. The prostanoids are made in a cell- ortissue-specific manner and mediate a diverse range of physiologic rolesin the body. By way of example, TXA₂ is predominantly made in plateletsand in activated macrophages. Thus, inhibiting COX, such as withinplatelets or macrophage, should reduce or prevent the synthesis of TXA₂.

Non-steroidal anti-inflammatory drugs (NSAIDs), such as aspirin, inhibitCOX, thus interfering with the synthesis of TXA₂. However, since COXproduces the other physiologically important prostanoids, NSAIDs cancause a general imbalance in prostanoid levels. This imbalance canactually increase the risk of thrombosis, leading to stroke and otherproblems. Furthermore, a large part of the population exhibits aspirinresistance. Also problematic, COX inhibitors are associated with theirritation of gastric mucosa, peptic ulceration, and renal failure.

Of note was the discovery that the COX enzyme exists as two distincttypes or isoenzymes referred to as COX-1 and COX-2. Since COX-1inhibition was thought to cause gastric irritation, selective inhibitorsof COX-2 (coxibs) were developed. However, the coxibs have not provensatisfactory. For instance, coxibs appear to increase the risk ofatherothrombosis and myocardial infarction, even with short-term use.Notably, the coxib Vioxx was withdrawn from the market after its use wasshown to be associated with adverse thromboembolic events.

Given these problems with COX inhibitors, there is clinical interest inblocking the function of TXA₂ by blocking the TXA₂ receptor (the Tprostanoid receptor, or in short the TP) at the platelet surface. Acompound that binds to the TP antagonistically should inhibit TXA₂binding and platelet aggregation and thus thrombosis. Furthermore, asthe primary COX-1/COX-2 product PGH₂, an endoperoxide, also binds andactivates the TP, antagonists of the TP should also impair itsactivation by PGH₂. Moreover, in addition to its enzymatic conversioninto the prostanoids through the COX-1/COX-2 catalyzed reactions,arachidonic acid can also be converted non-enzymatically into theisoprostanes through free-radical mechanisms. Noteworthy, theisoprostane 8-iso-PGF_(2α), is the most abundant isoprostane generatedduring oxidative injury and actually mediates its actions/signalsthrough the TP. Hence, selective TP antagonists will have the addedadvantage over COX-1/COX-2 inhibitors, such as aspirin or coxibs, inthat they will also inhibit the adverse actions of the isoprostane8-iso-PGF_(2α), generated during oxidative injury and of theendoperoxide PGH₂, in addition to inhibiting the action of TXA₂ itself.Unfortunately, existing TP antagonists have proven problematic. Forexample, they lack efficacy, TP specificity and target other receptors,such as the PGD₂, platelet activating factor 4, or Leukotriene D₄receptors.

In humans and primates, but not in other species, TXA₂ actually signalsthrough two distinct TP receptor isoforms referred to as TPα and TPβwhich are encoded by the same gene and differ exclusively in theirdistal carboxy-terminal primary amino acid sequences. Furthermore, thecurrent TP antagonists do not discriminate between the two TPα and TPβreceptor isoforms which play similar, but not identical, roles. TPα, forexample, is subject to desensitization in ways that TPβ is not and viceversa. Due to their distinct roles, in addition to developing general TPantagonists, there may also be clinical interest in compounds that canselectively interact with one or both isoforms of the TP.

SUMMARY

The invention generally provides compounds that bind to thromboxane (TX)A₂ receptors (TP) and inhibit thrombosis and other events within thecardiovascular, renal or pulmonary systems. Compounds of the inventionprevent TXA₂, and other incidental ligands including the endoperoxidePGH₂ and the isoprostane 8-iso-PGF_(2α), from binding to the TP andstimulating platelet activation and aggregation, thereby decreasing therisk of a clinically significant thrombus or embolus, or binding andactivating the TPα and/or TPβ isoforms expressed in cells of thecardiovascular, renal or pulmonary systems. Thus, the TP antagonists ofthe invention provide beneficial pharmaceutical properties for treatingthrombosis and other events within the cardiovascular, renal orpulmonary systems. The invention further provides compounds thatselectively bind to either the TPα and/or TPβ form of the TXA₂ receptor(the TP).

Compounds of the invention include any compound that prevents orattenuates thrombosis by binding antagonistically to the TP and thatpreferably do not specifically bind to non-thromboxane receptors orother proteins.

In certain aspects, the invention provides a TP antagonist, or apharmaceutically acceptable salt thereof, which includes a substitutednitro-phenoxy phenyl, a sulfonylurea, and an alkyl group. In someembodiments, the alkyl group is either an isopropyl group, a pentylgroup, a tert-butyl group, or a cyclohexyl group.

In certain embodiments, the TP antagonist is represented by formula (I):

in which R¹ is an alkyl group and R² is either a halogen, an alkylgroup, or an aryl group.

The invention further provides compounds of formula (I), in which R¹ isan isopropyl group, a pentyl group, a tert-butyl group, and a cyclohexylgroup and R² is one of:

I,

with R³ being OH, I, CH₃, CO₂Me, CO₂H, or

As used herein, * represents the point of attachment.

In certain embodiments, the TP antagonist is represented by one of theformulas (II), (III), (IV), (V), (VI), (VII), (VIII), (IX), (X), and(XI):

In which R⁴ is

I,

R⁵ is one of I and

R⁶ is I,

R⁷ is I,

R⁸ is I,

In certain embodiments the TP antagonist is represented by formula(XII):

In certain embodiments the TP antagonist is represented by formula(XIII):

in which R⁹ is

or a pharmaceutically acceptable salt thereof.

In certain embodiments, the TP antagonist is represented by one of theformulas (XIV), (XV), (XVI), (XVII), (XVIII), (XIX), (XX), and (XXI):

In certain embodiments, the TP antagonist is represented by formula(XXII):

in which R¹⁰ is

H, NH₂, I,

and CO₂Me.

In certain embodiments, the TP antagonist is represented by formula(XXII):

wherein R¹⁰ is selected from the group consisting of

and Cl, or a pharmaceutically acceptable salt thereof.

In certain embodiments, the TP antagonist is represented by one of(LVII), (LVIII), (LIX), and (LX):

or a pharmaceutically acceptable salt thereof.

In certain aspects, the invention provides a method of treating acondition that involves administering an effective dose of anantithrombotic compound, or a pharmaceutically acceptable salt thereof.The antithrombotic compound or the salt thereof can be one thatspecifically binds to a TP and preferably does not specifically bind tonon-thromboxane receptors. In some embodiments, the antithromboticcompound exhibits preferential binding for either TPα and/or TPβreceptor subtype.

Exemplary conditions treatable by methods of the invention includeatherothrombosis, stroke, myocardial infarction, atherosclerosis,arteriosclerotic vascular disease, thromboembolism, deep veinthrombosis, arterial thrombosis, ischemia, peripheral vascular disease,peripheral artery occlusive disease, coronary artery disease, anginapectoris, and transient ischemic attack, various renal (e.g.glomerulonephritis, proteinuria including that associated with types Ior II diabetes mellitus etc.) and pulmonary diseases (e.g., asthma.Pulmonary arterial hypertension etc.). Compounds of the invention may beused to treat cardio-vascular diseases (CVDs), atherothrombotic eventsassociated with acute coronary syndrome (ACS), or other conditions. Insome embodiments, the invention provides compounds for reducing cerebro-and cardio-vascular episodes in patients with a history of ischemicstroke or transient ischemic attack or for the acute post-operativemanagement of at-risk patients following certain surgical orintervention procedures.

In certain aspects, the invention provides an implantable medical devicecomprising a compound of the invention and methods of delivering acompound of the invention via a temporary or permanent or retrievable orbioabsorbable or bio-erodable device or implant. Devices and methods ofthe invention can provide an antithrombotic compound in a stent (e.g., adrug eluting stent (DES)) or a balloon (e.g., a drug eluting balloon).In a preferred embodiment, the compound has formula (X).

The TP antagonist molecules of the invention such as the compound havingformula (X) provide ideal drugs as a coating agent on DES, as well as onbifurcation stents, by-pass graft vessel stent and medical devices usedto treat stroke or other cardiovascular episodes or diseases. Compoundsof the invention and implantable devices comprising the compounds mayexhibit any of a number of salutary effects, including: prevention ofplatelet aggregation and secretion at sites of local vessel damage;reduction of the inflammatory effects of elevated levels of TXA₂ atsites of local vessel damage; prevention of TXA₂-induced smooth musclecell proliferation, neo-intima thickening, and restenosis (which isprimarily driven by elevated levels of TXA₂ and/or PGH₂ at the damagedblood vessel wall); and inhibition of the undesirable actions of8-iso-PGF_(2α) within a damaged blood vessel. Compounds and devices ofthe invention in combination with very low levels of sirolimus and/orpaclitaxel will be synergistic in further preventing restenosis while atthe same time in eliminating and/or reducing the adverse effectsassociated with local, high levels of sirolimus or paxlitaxol. Byantagonizing the TP receptor on endothelial cells compounds of theinvention may prevent both TXA₂- and isoprostane(8-iso-PGF_(2α))-induced suppression of VEGF signaling, which in turnwill enable VEGF induced re-endothelialization and/or vascular repair,further preventing restenosis in response to TXA₂ or isoprostanes orother growth factor(s) released from activated platelets or macrophages.

In certain aspects, the invention provides an implantable medical devicecoated with a compound of the invention along with clot-dissolvingagents such as tissue plasminogen activator (tPA) or urokinase, theirderivatives or other such agents which will act synergistically to bothlyse and dissolve clots in the vicinity of the stent or balloon as wellas preventing future clot formation, such as in the treatment ofischemic or cerebral stroke. Such dual coatings can also be incorporatedinto clot retriever systems.

A stent according to the invention comprises a compound of the inventionand may have an expandable structure. A stent may be formed at least inpart from an open lattice. In some embodiments, the invention providesan implantable medical device coated with a compound of the invention,preferably having formula (X).

BRIEF DESCRIPTION OF THE DRAWINGS

FIGS. 1A and 1B show the effect of the TP antagonist compounds of theinvention on U46619-mediated calcium mobilization in HEK.TPα and HEK.TPβcells

FIG. 2 shows the effect of the TP antagonists on U46619-mediated calciummobilization in HEK.TPβ cells.

FIG. 3 illustrates effects of the TP antagonist compounds onU46619-mediated platelet aggregation.

FIG. 4A-4C show the effect of TP20 & NTP4 on U46619-mediated plateletaggregation

DETAILED DESCRIPTION

The invention generally relates to compounds that prevent or attenuatethrombosis by binding antagonistically with TP to prevent the binding ofTXA₂, PGH₂ and/or isoprostanes including 8-iso-PGF_(2α). Compounds ofthe invention include those that exhibit preferential binding for eitherTPα and/or TPβ receptor subtype. As discussed herein, the inventionprovides small molecule antithrombotic compounds, which inhibit plateletaggregation and exhibit attractive ADME (absorption, distribution,metabolism, and excretion) properties. The invention further providesexemplary synthetic routes for antithrombotic compounds by way ofexample but not exhaustive of all routes of synthesis. Exemplarycompounds of the invention are disclosed.

In some embodiments, compounds of the invention display significant TPselectivity and antagonistic activity ex vivo in human platelets and areeffective in preventing in vivo thrombosis in rodents using the ferricchloride model, as discussed, for example, in U.S. Pub. 2005/0025705,herein incorporated by reference in its entirety.

Compounds of the invention preferably inhibit TXA₂-induced plateletaggregation at a half-maximal inhibitory concentration (IC₅₀) below 100nM. Compounds of the invention preferably inhibit TXA₂-induced plateletaggregation at a half-maximal inhibitory concentration (IC₅₀) below 50nM. Compounds of the invention preferably inhibit TXA₂-induced plateletaggregation at a half-maximal inhibitory concentration (IC₅₀) below 20nM. Compounds of the invention preferably inhibit TXA₂-induced plateletaggregation at a half-maximal inhibitory concentration (IC₅₀) below 5nM. In certain embodiments, compounds of the invention further inhibitTXA₂-induced platelet aggregation but not aggregation induced by otherplatelet agonists such as, for example, thrombin or adenosinediphosphate (ADP). Further, compounds of the invention preferably do notagonize or antagonize signaling by several other G-protein coupledreceptors, kinases, phosphatases, or ion channels including humanEther-á-go-go related gene (hERG).

Compounds of the invention exhibit attractive ADME properties. In someembodiments, compounds have a half-life of 20 minutes and more than 200minutes in rat hepatic microsomes and plasma, respectively. Inventivecompounds have greater than 50% oral bioavailability and a 4.5 hourelimination half-life for oral delivery. In some embodiments, inventivecompounds exhibit 1.4 ml/min/kg clearance rates following I.V. deliveryand are neither cytotyoxic or genotoxic. TP antagonists of the inventionexhibit the ability to inhibit agonist-induced intracellular calciummobilization and inhibit platelet aggregation in ex vivo assays. In someembodiments, compounds of the invention show no effect on signalingthrough other prostanoid (prostaglandin (PG) I₂ receptor, IP; PGE₂receptors EP₃ and EP₁; PGF_(2α) receptor, FP) and non-prostanoidreceptors including the purinergic (ADP) and thrombin (PAR1) receptors,also involved in platelet activation similar to the TP isoforms.Further, compounds exhibit minimal toxicity and favorable cellpermeability.

Shown below are exemplary methods of synthesis of compounds of theinvention.

First, 2-Chloro-5-nitrobenzenesulfonamide is synthesized according toPathway A.

Sodium nitrite (4.96 g; 72 mmol) dissolved in water (11 mL) was addeddrop wise over 30 minutes to a cooled solution (−5° C.) of2-chloro-5-nitroaniline (1; 10.00 g; 58 mmol) in 12M HCl (104 mL). Whilestirring at −5° C. for a further 30 minutes, a solution of copper(II)chloride dissolved in water (4 mL) was poured into acetic acid (110 mL)previously saturated with sulphur dioxide (gas). This was then added tothe diazonium salt 2 solution and stirred until nitrogen gas ceased toevolve. The reaction mixture was quenched with ice-water and thesubsequent precipitate formed was collected by filtration and washedwith cold water. Aqueous ammonium hydroxide (35%) (120 mL) was added tothe resulting sulfonyl chloride 3 and stirred for 18 hours. The solutionwas then filtered and the resulting filtrate was acidified using 12M HClto precipitate the title compound 4 (7.55 g; 55% over 3 steps). M.p186-187° C. (lit. 177-179° C.)

From this point, Pathway B was used for the synthesis of2-(3-Iodophenoxy)-5-nitrobenzenesulfonamide 6.

An aqueous solution of NaOH (3.66 g; 92 mmol; 10% w/v) was added to asolution of 3-iodophenol (18.30 g; 83 mmol) in acetone (130 mL).Evaporation under reduced pressure afforded the crystals of the sodiumsalt 5, which were added to a solution of sulfonamide 4 (3.94 g; 17mmol) in acetonitrile (24 mL). The mixture was refluxed and potassiumcarbonate (1.62 g; 12 mmol) was added. After completion of the reaction(48 h, monitored by TLC), the solution was acidified using 12M HCl,diluted with water and extracted with ethyl acetate (×3). The combinedorganics were dried (MgSO₄), and concentrated in vacuo. The crudeproduct was purified using column chromatography (SiO₂; pentane/ethylacetate, 3:1), yielding the title compound 6 as a colorless solid (5.84g; 84%). M.p. 153-155° C. (lit. 153-154° C.).

From this point, 2-(3-Iodophenoxy)-5-nitrobenzene(t-butyl)sulfonyl urea(Formula XXXVIII) was prepared according to Pathway C.

NaOH (122 mg; 3.04 mmol) dissolved in water (10% w/v) was added to asolution of sulfonamide 6 (1279 mg; 3.04 mmol) in acetone (10 mL). Themixture was stirred for 10 minutes, then the solvent was evaporated invacuo. The resulting sodium salt was resuspended in acetone (10 mL) andgently put under reflux, then t-butyl isocyante was added to the mixture(603 mg; 700 μL; 6.08 mmol). After 40 minutes the reaction mixture wasconcentrated under reduced pressure and the resulting solid was washedwith ethyl acetate, isolated by filtration and dissolved in an aqueoussolution of 0.5M NaOH. The subsequent solution that formed was acidifiedto pH 1 with 12 M HCl, and the precipitate that formed was collected byfiltration. This delivered the title compound 7 (Formula XXXVIII) withno further purification necessary (1484 mg; 94%). M.p. 233-236° C. (lit.154-157° C.).

Compound 8 (Formula XLI) and/or compound 9 (Formula X) are obtained viapathway D.

An aqueous degassed solution of potassium carbonate (4 mmol in 3.1 mLH₂O) was added to a schlenk tube containing aryl iodide 7 (1 mmol;Formula XXXVIII), the appropriate boronic acid (1.1 mmol), palladium(II)acetate (0.08 mmol) in DMF (3.1 mL) under nitrogen. The reaction mixturewas degassed and refilled with nitrogen 3 times, and then stirred atroom temperature for 24 hours. Upon completion of the reaction, themixture was diluted with water and extracted with ethyl acetate (×3),dried over MgSO₄ and concentrated in vacuo. The crude product waspurified using flash chromatography (8; SiO₂; pentane/diethyl ether,1:1) (9; SiO₂; pentane/diethyl ether, 1:2), isolating the titlecompounds (8; 63% (Formula XLI); 9; 58% (Formula X)). M.p. (8 210-212°C.; 9 194-197° C.).

Further description of preparation of sulfonylurea derivatives is givenin U.S. Pat. No. 5,434,124, incorporated by reference in its entirety.The preparation of p-nitrobenzenesulfonylurea fromp-nitrobenzenesulfonamide, through a p-nitrobenzenesulfonylisoureaintermediate, is described in U.S. Pat. Nos. 3,556,764 and 3,714,209,incorporated by reference herein in their entirety.

Through suitable variations of the pathways discussed herein, a varietyof substituted nitrobenzenesulfonylureas of formula (I) can be prepared:

In certain embodiments,N-(tert-butylcarbamoyl)-2-(3-methoxyphenoxy)-5-nitrobenzenesulfonamide(also known as CAY10535) is obtained. CAY10535 has formula (XXIII):

CAY10535 is available from Cayman Chemical (Ann Arbor, Mich.), and has amolecular formula of C₁₈H₂₁N₃O₇S and formula weight 423.4. CAY10535 canbe obtained as a crystalline solid. A stock solution is made bydissolving the compound in DMSO or ethanol with an inert gas. Forsolution in a aqueous buffer, CAY10535 is first dissolved in DMF andthen diluted in a desired aqueous buffer.

In certain embodiments, the palladium-catalyzed Suzuki reaction isfurther used to add one or more aryl groups, optionally containing oneor more substituents, to the above-described compounds. For example,where R² represents a para methyl group of a 4-methylphenol substituenton the oxygen bridge, that R² group can be replaced with an aryl group,including, for example, 4-methylphenyl or any other. Use of thepalladium-catalyzed Suzuki reaction is described in U.S. Pat. No.6,583,307 and U.S. Pat. No. 6,136,157, both of which are hereinincorporated by reference in their entirety.

In certain embodiments, compounds of the invention, for example assynthesized according to combinations of the above-described pathways,are described by formulas (XXIV), (XXV), (XXVI), (XXVII), (III),(XXVIII), (VIII), (XXIX), (XXX), (XXXI), (XXXII), (XXXIII), (XXXIV),(XXXV), (XXXVI), (XXXVII), (XXXVIII), (XXXIX), (IX), (XL), (XLI),(XLII), (XLIII), (XLIV), (X), (XLV), (XLVI), (XII), (XLVII), and (XI).

Further compounds of the invention are synthesized according to PathwayE. Synthesis according to Pathway E begins with a compound of formula(LII). Compounds synthesized according to Pathway E can include anymoiety known in the art at R¹³. Exemplary moieties for R¹³ include: I,CF₃, H, various organic groups, methoxy phenyl, methyl phenyl,trifluoromethyl phenyl, methyl ester, and H.

Compounds of the invention, for example, synthesized in-part accordingto Pathway E include compounds described by formulas (XVI), (XLVIII),(XVIII), (XLIX), (L), (LI), (LII), (LIII), (LIV), (LV), and (LVI):

Further compounds of the invention synthesized according to methodsknown in the art include compounds described by formulas (XXI), (XVII),(XIV), (XIX), (XV), and (XX):

In certain embodiments, the invention provides TP antagonist compounds,which include a substituted nitro-phenoxy phenyl, a sulfonylurea, and analkyl group. In some embodiments, the alkyl group is either an isopropylgroup, a pentyl group, a tert-butyl group, or a cyclohexyl group. Insome exemplary embodiments according to combinations of or modificationsto the above-described synthetic pathways, the invention provides a TPantagonist including a compound represented by formula (I):

in which R¹ is a tert-butyl group or a pentyl group and R² is I,

optionally in the para position.

In certain embodiments the TP antagonist is represented by formula(XIII):

in which R⁹ is

In some embodiments, it may be beneficial to replace the nitro group ofany of the foregoing compounds (e.g., the nitro group shown in formula(XIII) with a nitrile group (—CN) or other substituent.

The following synthetic pathways may be used to arrive at compounds ofthe present invention. Pathway F can be used to synthesize2-Chloro-5-nitrobenzenesulfonamide for use as an intermediate.

1-Chloro-4 nitrobenzene (6.93 g, 44 mmol) was added to chlorosulphonicacid (20 mL) and heated to 120° C. for 18 hours. After cooling to roomtemperature, the reaction was poured onto ice. The2-chloro-5-nitrobenzene sulfonic acid was extracted with dichloromethane(DCM) and the organic phase was washed with brine, dried over MgSO₄ andthen concentrated to dryness under vacuum. The reaction yielded 8.71 gof crude sulfonic acid and was used directly without furtherpurification.

2-chloro-5-nitrobenzenesulfonic acid (44 mmol) was heated at reflux for3.5 hours in a mixture of thionyl chloride (22 mL) and dimethylformamide(2 mL). After cooling the reaction mixture to room temperature, thesolvents were removed under high vacuum. The crude solid was azeotropedwith toluene (3×100 mL) to dryness under vacuum. The final residue wastaken up in a mixture of toluene (20 mL) and tetrahydrofuran (50 mL)then cooled to 0° C. Ammonia (50 mL) was added to the stirred reactionmixture, then allowed to warm to room temperature overnight. Thesolution was acidified using 6 M HCl (pH˜4) and extracted with ethylacetate (3×100 mL). The combined organics were dried over MgSO₄,filtered and then concentrated to dryness under vacuum to yield2-Chloro-5-nitrobenzenesulfonamide as a light brown solid (3.91 g, 38%over 2 steps).

Pathway G yields 4′-methoxy-[1,1′-biphenyl]-3-ol.

Nitrogen was bubbled through a mixture of 1-bromo-4-methoxybenzene (5.0g, 26.8 mmol), 3-hydroxyphenylboronic acid (6.8 g, 49.6 mmol), aqueouspotassium carbonate (2 M, 20 mL, 40 mmol), acetone (170 mL) and H₂O (300mL) for 5 minutes. Pd(OAc)₂ (800 mg, 3.55 mmol) was added and themixture was stirred under a nitrogen atmosphere at room temperature for20 minutes, after which time LC-MS analysis showed the reaction to becomplete. The reaction mixture was concentrated under vacuum thendiluted with ethyl acetate (200 mL). The resulting suspension wasfiltered through a pad of celite, and the aqueous phase was thenseparated and extracted with EtOAc (2×100 mL). The combined organicswere dried over MgSO₄, filtered and concentrated to dryness undervacuum. The crude product was loaded onto a 340 g Biotage silicacartridge and purified by Biotage chromatography (eluting withiso-hexane/EtOAc, gradient 0 to 50%). The target compound4′-methoxy[1,1′-biphenyl]-3-ol was isolated as a white solid (5.66 g,78% yield).

Pathway H produced2-((4′-methoxy-[1,1′-biphenyl]-3-yl)oxy)-5-nitrobenzenesulfonamide.

An aqueous solution of NaOH (10% w/v, 1.1 g, 27.5 mmol) was added to asolution of the phenol (5.5 g, 29.5 mmol) in acetone (100 mL). Thesolvents were removed under vacuum to afford the sodium salt, which wasadded to a solution of sulfonamide (5 g, 21.13 mmol) in acetonitrile(100 mL). The mixture was heated to reflux, potassium carbonate (2.0 g)was added and the mixture was heated at reflux for a further 18 hours.The reaction mixture was concentrated under vacuum, diluted with water(25 mL) and acidified with concentrated HCl (pH˜1). The aqueous phasewas extracted with EtOAc (3×50 mL) and the combined organic phases werewashed with brine, dried over MgSO₄, filtered and concentrated todryness. The crude product was loaded onto a Biotage silica cartridge(100 g) and purified by Biotage chromatography (eluting withiso-hexane/EtOAc gradient 0 to 50%). The target compound nitrobenzenesulfonamide was isolated as an off white solid (7, 1.0 g, 50%).

Pathway I can be used to produceN-(tert-butylcarbamoyl)-2-((4′-methoxy-[1,1′-biphenyl]-3-yl)oxy)-5-nitrobenzene-sulfonamiderepresented by formula (X).

A solution of the sulfonamide (2.1 g, 5.24 mmol) in acetone (30 mL) wastreated with a solution of potassium hydroxide (295 mg, 5.24 mmol) inwater (1.8 mL). After stirring the reaction at room temperature for 15minutes, the solvents were removed under vacuum. The residue wasdissolved in DMF (30 mL), tert-butylisocyanate (1.2 mL, 10.4 mmol) wasadded and the reaction mixture was stirred at room temperature for 18hours. The solvents were removed under high vacuum and the crude productwas loaded onto a 50 g Biotage silica cartridge and purified by Biotagechromatography (eluting with 1-100% gradient iso-hexane/EtOAc). Thecrude product was re-dissolved in DMF (15 mL), NaH (60% in oil, 35 mg,0.87 mmol) was added, followed by tert-butylisocyanate (110 μl, 0.95mmol). The mixture was stirred at room temperature for 4 hours and thenevaporated under high vacuum before loading onto a 50 g silicacartridge. The crude product was purified by Biotage chromatography(eluting 1-100% gradient iso-hexane/EtOAc), obtaining the title compoundas an off white solid (Formula (X), 2.6 g, 99%).

5-amino-N-(tert-butylcarbamoyl)-2-((4′-methoxy-[1,1′-biphenyl]-3-yl)oxy)benzene-sulfonamide,or Formula (LII) is made from Formula (X) according to Pathway J.

The nitrobenzene sulphonylurea (Formula (X), 2.6 g, 5.2 mmol) was heatedwith iron powder (1.74 g, 31 mmol), ethanol (15 mL), acetic acid (15 ml)and H₂O (7.5 mL) at 55° C. for 3 hours. After cooling to roomtemperature the reaction was diluted with EtOAc, the resultingsuspension was then filtered through a small pad of celite. The filtratewas washed with 2 M KOH and the aqueous layer was extracted with EtOAc.The combined organics were washed with brine, dried over MgSO₄, filteredand concentrated under vacuum to yield the desired product as an offwhite solid (Formula (LII), 2.4 g, 98% yield).

Pathway K yieldsN-(tert-butylcarbamoyl)-5-chloro-2-((4′-methoxy-[1,1′-biphenyl]-3-yl)oxy)benzenesulfonamide (Formula (CX)).

The amino benzene sulfonamide (Formula (LII), 150 mg, 0.3198 mmol) wasdissolved in acetonitrile (3 mL) and cooled to 0° C. Concentrated HCl(400 μL) was then added, followed by NaNO₂ (26.5 mg, 0.3838 mmol) andthe mixture was then stirred for 20 minutes. A solution of Cu(I)Cl (63.3mg, 0.6396 mmol) in H₂O (1 mL) was added and the mixture was stirred fora further 18 hours, allowing to warm to room temperature, after whichtime LC-MS analysis showed 5-10% conversion. Further Cu(I)Cl (60 mg) wasadded to the reaction and after heating to 65° C. for a further 3 hours,full conversion was confirmed by LC-MS. The reaction mixture wasconcentrated under vacuum and then diluted with water. The aqueous phasewas extracted with EtOAc (3×50 mL). The combined organic phases werewashed with brine, dried over MgSO₄, filtered and concentrated todryness under vacuum. The crude solid was dissolved in acetone (2 mL)and added to a solution of KOH (1.8 mg) in H₂O (300 μL). The reactionmixture was stirred for 20 minutes before concentrating to dryness undervacuum. The solid was dissolved in DMF (2 mL) and tert-butylisocyanate(23 μL) was added and the reaction was stirred for 18 hours. The crudeproduct was filtered through a syringe filter before purifying bypreparative HPLC to give the desired product as an off-white solid(Formula (CX), 50 mg, 32% yield).

Pathway L makes5-bromo-N-(tert-butylcarbamoyl)-2-((4′-methoxy-[1,1′-biphenyl]-3-yl)oxy)benzenesulfonamiderepresented by formula (LXI).

Hydrobromic acid (48%, 3.6 mL) was added to a stirred solution of NaNO₂(318 mg, 4.606 mmol) and amino benzene sulfonamide (Formula (LI), 1.8mg, 3.838 mmol) in CH₃CN (40 mL) and water (9 mL) at 0° C. The reactionmixture was maintained at 0° C. for 15 minutes and Cu(I)Br (1.21 g,8.4436 mmol) was added. The mixture was allowed to warm to roomtemperature over 18 hours. The reaction mixture was diluted with water(50 mL) and extracted with EtOAc (3×100 mL). The combined organics weredried over MgSO₄, filtered and concentrated to dryness under vacuum. Thecrude product was loaded onto a 100 g silica cartridge and purified byBiotage chromatography (eluting with iso-hexane/EtOAc, gradient 0 to100%), to yield the target compound5-bromo-N-(tert-butylcarbamoyl)-2-((4′-methoxy-[1,1′-biphenyl]-3-yl)oxy)benzenesulfonamideas a white solid (Formula LXI, 0.92 g, 96.4%).

Pathway M provides for the synthesis of an intermediateN-(tert-butylcarbamoyl)-5-cyano-2-((4′-methoxy-[1,1′-biphenyl]-3-yl)oxy)benzenesulfonamide,formula (LXII), from the compound represented by formula (LI).

To a solution of the amino benzene sulfonamide (Formula (LI), 100 mg,0.213 mmol) in acetone (10 mL) and water (1 mL) at 0° C., hydrochloricacid (37%, 500 μl) was added, followed by a solution of NaNO₂ (18 mg,0.26 mmol) in H₂O (1 mL). The reaction mixture was stirred at 0° C. for20 minutes after which time it was poured onto a solution of NaCN (45mg, 0.92 mmol) and CuCN (30 mg, 0.33 mmol) in H₂O (10 mL) and EtOAc (5mL), stirring at room temperature for 4 hours. The reaction mixture wasdiluted and extracted with EtOAc (3×100 mL). The combined organics werewashed with brine, dried over MgSO₄, filtered and then concentrated todryness under vacuum. The crude product was diluted with DMSO (1.5 mL)and then purified by preparative HPLC to yield the target compoundN-(tert-butylcarbamoyl)-5-cyano-2-((4′-methoxy-[1,1′-biphenyl]-3-yl)oxy)benzenesulfonamideas a white solid (Formula (LXII), 7.51 mg, 7.3%).

Synthesis of various compounds from compound represented by formula(LXI) is described.

In some embodiments, a test Suzuki providesN-(tert-butylcarbamoyl)-5-(1-ethyl-1H-pyrazol-4-yl)-2-((4′-methoxy-[1,1′-biphenyl]-3-yl)oxy)benzenesulfonamide,formula (LXIII), from compound represented by formula (LXI) provided byPathway L, as described below in Pathway N.

The bromo benzene sulfonamide (Formula (LXI), 50 mg, 0.09375 mmol),Pd(PPh₃)₄ (10.8 mg, 0.009375 mmol), Cs₂CO₃ (73.11 mg, 0.2249 mmol),dioxane (1 mL), EtOH (0.5 mL), H₂O (0.15 mL) and the boronate (61 mg,0.1875 mmol) were added to a stem tube under N₂. The reaction tube wasdegassed for 5 minutes, sealed and then heated to 80° C. for 18 hours,after which time LC-MS analysis showed ˜60% conversion. The solventswere removed under vacuum and the residue was diluted with water andextracted with DCM. The organic phase was removed and concentrated todryness under vacuum. The crude product was dissolved in DMSO (1.5 mL)and then purified by preparative HPLC to yield the target compound as anoff-white solid (Formula (LXIII), 14.4 mg, 28%).

Using C-Linked palladium array chemistry, as shown in Pathway O below,arrives at a number of compounds based on the compound represented byformula (XXII) and starting with the compound represented by formula(LXI). This is shown in Pathway O, below, where Table 1.1 shows whichboronate compound reactant and in what amount to use to yield whichproduct.

TABLE 1.1 C-Linked Palladium Array Chemistry Amount (mg); BoronateAmount (mmol); reactant Yield (mg, %) Target Compound/product

49.63; 0.1687; 20 mg, 17%

37.64; 0.1687; 6 mg, 9%

18.88; 0.1687; 33 mg 56%

18.88; 0.1687; 33 mg, 56%

20.74; 0.1687; 7.8 mg, 13%

For each of the target reactions, bromo benzene sulfonamide (Formula(LXI), 60 mg, 0.1125 mmol), Pd(PPh₃)₄ (13 mg, 0.01125 mmol), Cs₂CO₃(73.11 mg, 0.2249 mmol), dioxane (1 mL), EtOH (0.5 mL), H₂O (0.15 mL)and the corresponding boronates, as indicated in Table 1.1, were addedto a stem tube under N₂. The reaction tubes were degassed for 5 minutes,sealed and then heated to 80° C. for 18 hours. The solvents were removedunder vacuum and diluted with water, then extracted with DCM. Theorganic phase was removed and concentrated to dryness under vacuum. Thecrude products were dissolved in DMSO (1.5 mL) and then purified bypreparative HPLC to yield the desired target compounds represented byformulas (LXIV), (LXV), (LXVI), (LXVII), and (LXVIII) with yields asindicated in Table 1.1.

The Stille reaction shown in Pathway P can produceN-(tert-butylcarbamoyl)-2-((4′-methoxy-[1,1′-biphenyl]-3-yl)oxy)-5-(2-methoxythiazol-4-yl)benzenesulfonamide,formula (LXIX), from (LXI).

Pd(PPh₃)₄ (13 mg, 0.01125 mmol) was added to a N₂ flushed reaction tubecontaining the sulphonamide (Formula (LXI), 60 mg, 0.1125 mmol), DMF(1.5 mL) and the tributyl stannyl thiazole (68 mg, 0.1688 mmol). Thereaction tube was flushed with N₂ before sealing the tube and heating to80° C. for 18 hours, after which time, LC-MS analysis confirmed completeconversion. The crude product was filtered and then purified bypreparative HPLC to yield the product as a white solid (Formula (LXIX),29 mg; 45%).

Pathway Q, shown below, produces5-acetyl-N-(tert-butylcarbamoyl)-2-((4′-methoxy-[1,1′-biphenyl]-3-yl)oxy)benzenesulfonamide,formula (LXX), from (LXI).

The tributyl-(1-ethoxyvinyl)stannane (67.7 mg, 0.1875 mmol) was added toa solution of the bromo-benzenesulfonurea (Formula (LXI), 80 mg, 0.150mmol) in DMF (1.5 mL) under N₂. Pd(PPh₃)₄ (17 mg, 0.015 mmol) was addedand the reaction tube was flushed with N₂, sealed and then heated to 80°C. for 18 hours. LC-MS analysis showed near complete reaction to thevinyl ether intermediate. The DMF was removed under high vacuum and HCl(2M, 1 mL) was added followed by THF (1 mL). The reaction was stirredfor 1 hour after which time LC-MS analysis confirmed complete conversionto the desired product. The solvents were removed under vacuum and theresidue was diluted with water, extracting with DCM. The organic phasewas removed and concentrated to dryness under vacuum. The crude productswere dissolved in DMSO (1.5 mL) and purified by preparative HPLC toyield the target compound as a white solid (Formula (LXX), 15.2 mg,20%).

Methyl 4-fluoro-3-sulfamoylbenzoate, formula (LXXI) is a product ofpathway R and an intermediate in synthetic pathways disclosed herein.

Thionyl chloride (3 mL) was added to a solution of4-fluoro-3-sulfamoylbenzoic acid (1.8 g, 8.91 mmol) in methanol (100mL). The resulting mixture was heated at 70° C. for 3 hours and thenevaporated to dryness under vacuum. The resulting crude solid wasre-dissolved in DCM and washed with water. The organic phase was driedover MgSO₄, filtered and evaporated to dryness to provide desiredproduct as a beige solid (Formula (LXXI), 1.5 g, 78% yield).

In Pathway S, Methyl4-((4′-methoxy-[1,1′-biphenyl]-3-yl)oxy)-3-sulfamoylbenzoate, Formula(LXXII), is produced.

An aqueous solution of NaOH (40% w/v, 380 mg, 27.5 mmol) was added to asolution of the phenol (1.9 g, 9.5 mmol) in acetone (50 mL). Thereaction mixture was stirred for 10 minutes then evaporated to drynessunder high vacuum. The residue was dissolved in acetonitrile (60 mL) andthen the sulfonamide (Formula (LXXI), 2.0 g, 8.6 mmol) and potassiumcarbonate (840 mg) were added. The resulting mixture was heated to 90°C. for 18 hours. The solvents were removed under vacuum and the crudesolid obtained was partitioned between water and EtOAc (100 mL),acidifying to pH˜1 with concentrated HCl. The aqueous phase was removedand re-extracted with EtOAc (2×100 mL) and the combined organic phaseswere washed with brine, dried over MgSO₄, filtered and evaporated todryness. The crude product was loaded with DCM, onto a silica cartridge(25 g) and then purified by Biotage chromatography (eluting withiso-hexane/EtOAc gradient 20 to 100% EtOAc). The target compoundnitrobenzene sulfonamide was isolated as a white solid (Formula (LXXII),2.64 g, 75%).

Pathway T produces Methyl3-(N-(tert-butylcarbamoyl)sulfamoyl)-4-((4′-methoxy-[1,1′-biphenyl]-3-yl)oxy)benzoate, represented by formula (LXXIII), from compound formula(LXXII).

Sodium hydride (60% in oil, 281 mg, 7.0 mmol) was added to a solution ofthe nitrobenzene sulfonamide (Formula (LXXII), 2.64 g, 6.4 mmol) in DMF(50 mL). The mixture was stirred for 10 minutes at ambient temperaturebefore the addition of tert-butylisocyanate (1 mL, 8.7 mmol). Theresulting mixture was stirred overnight at room temperature. Thesolvents were removed under high vacuum and then the crude solidobtained was partitioned between water and EtOAc (50 mL), beforeacidifying the aqueous with 1 M HCl (pH˜1). The aqueous phase wasremoved and re-extracted with EtOAc (2×50 mL) and the combined organicphases were dried over MgSO4, filtered and evaporated to dryness undervacuum to yield the desired product (Formula (LXXIII), 2.8 g, 86%).

Below,3-(N-(tert-butylcarbamoyl)sulfamoyl)-4-((4′-methoxy-[1,1′-biphenyl]-3-yl)oxy)benzoic acid, formula (LXXIV) is produced from (LXXIII) by pathway U.

Lithium hydroxide monohydrate (262 mg, 6.243 mmol) was added to asolution of the methyl ester (Formula (LXXIII), 2.0 g, 3.902 mmol) inTHF (100 mL) and H₂O (33 mL). The mixture was stirred at roomtemperature for 18 hours and then evaporated to dryness under vacuum.The residue was dissolved in H₂O and acidified using concentrated HCl(pH˜1). The resulting white solid was removed by filtration,re-dissolved in EtOAc (50 mL), and dried by passing through ahydrophobic filter before evaporating to dryness under vacuum to givethe desired product as a white solid (Formula (LXXIV), 1.7 g, 87%yield).

Synthesis of various compounds from the compound represented by formula(LXXIV) is described.

Pathway V shows synthesis of3-(N-(tert-butylcarbamoyl)sulfamoyl)-4-((4′-methoxy-[1,1′-biphenyl]-3-yl)oxy)-N,N-dimethylbenzamide,formula (LXXV), from compound formula (LXXIV).

The amine (16 mg, 0.196 mmol), HATU (71 mg, 0.1868 mmol) and DIPEA (120μL) were successively added to a solution of the acid (Formula LXXIV),85 mg, 0.170 mmol) in DMF (4 mL). The resulting mixture was stirred atroom temperature for 18 hours, after which time LC-MS analysis confirmed˜80% conversion to the target compound. The DMF was removed under highvacuum and the residue taken up in in EtOAc (20 mL) and H₂O (10 mL). Theaqueous phase was acidified using concentrated HCl (pH˜2) and thenextracted with EtOAc (2×20 mL). The combined organics were dried overMgSO₄, filtered and evaporated to dryness. The crude product wasdissolved in DMSO (1.5 mL), filtered and then purified by preparativeHPLC to yield a white solid (Formula (LXXV), 41 mg, 98.3%).

Pathway W shows an amide array synthesis of various amides as listed inTable 1.2 from compound Formula (LXXV).

TABLE 1.2 Amide Array: Synthesis of various amides from (LXXV) Amount(mg); Amount (mmol); Amine Yield (mg; %) Target Compound

16.25; 0.2407; 54 mg; 65%

10.85; 0.2407; 28 mg; 33%

NH₄Cl 12.88; 0.2407; 49 mg; 61%

20.97; 0.2407; 31 mg; 34%

18.08; 0.2407; 63 mg; 71%

21.22; 0.2407; 33 mg; 36%

17.12; 0.2407; 59 mg; 66%

13.74; 0.2407; 12.8 mg; 15% & 23 mg; 27%

22.42; 0.2407; 28 mg; 30%

26.03; 0.2407; 53 mg; 56%

20.24; 0.2407; 16.5 mg; 19%

17.59; 0.2407; 49 mg; 55%

Generic methods of amide coupling are described.

For each of the target reactions (e.g., Pathway W and Table 2.1), theamine (0.2407 mmol), HATU (114.3 mg, 0.301 mmol) and Hunigs base (167.4μL) were successively added to a solution of the acid 20 (80 mg, 0.16046mmol) in DMF (1.5 mL). The resulting mixture was stirred at roomtemperature for 18 hours. The DMF was removed under high vacuum and theresidue was partitioned between EtOAc (20 mL) and H₂O (10 mL). Theaqueous phase was acidified using concentrated HCl (to pH˜2) andextracted with EtOAc (2×20 mL). The combined organics were dried overMgSO₄, filtered and evaporated to dryness under vacuum. The crudeproducts were re-dissolved in DMSO (1.5 mL), filtered and then purifiedby preparative HPLC to yield the desired products with formulas (LXXVI),(LXXVII), (LXXVIII), (LXXIX), (LXXX), (LXXXI), (LXXXII), (LXXXIII),(LXXXIV), (LXXXV), (LXXXVI), and (LXXXVII), as shown in Table 2.1.

Pathway X, below, shows the synthesis ofN-(tert-butylcarbamoyl)-5-(3-hydroxyazetidine-1-carbonyl)-2-((4′-methoxy-[1,1′-biphenyl]-3-yl)oxy)benzenesulfonamide,formula (LXXXVIII) from compound formula (LXXV).

Azetidin-3-ol hydrochloride (26.4 mg, 0.240 mmol), HATU (67 mg, 0.1767mmol) and DIPEA (112 μL, 0.642 mmol) were successively added to asolution of acid (Formula (LXXV), 80 mg, 0.161 mmol) in DMF (2 mL). Theresulting mixture was stirred at room temperature for 4 hours. The DMFwas removed under high vacuum and the residue taken up in EtOAc and H2O.The aqueous phase was acidified using concentrated HCl (to pH˜2) andextracted with EtOAc (2×20 mL). The combined organics were dried overMgSO4, filtered and evaporated to dryness under vacuum. The crudeproduct was dissolved in DMSO (˜1.5 mL), filtered and then purified bypreparative HPLC to yield the title compound as a white solid (Formula(LXXXVIII), 19.2 mg, 21.5%).

Synthesis of various compounds is now shown.

Synthesis of N-(tert-butylcarbamoyl)-2-chloro-5-(trifluoromethyl)benzene-sulfonamide, formula (XC), from (LXXXIX) is shown in Pathway Y.

Sodium hydride (60% oil dispersion, 105 mg, 2.6 mmol) was added to asolution of 2-chloro-5-(trifluoromethyl)benzenesulfonamide (Formula(LXXXIX), 612 mg, 2.36 mmol) in DMF (30 mL). The mixture was stirred atroom temperature for 10 minutes prior to the addition oftert-butylisocyanate (380 μL, 3.30 mmol). The resulting reaction mixturewas stirred overnight at room temperature. The DMF was removed underhigh vacuum and the crude solid was re-dissolved in EtOAc and H₂O, thenacidified using 1 N HCl (pH=1). The aqueous phase was extracted withEtOAc and the combined organic phases were dried over MgSO₄, filteredand evaporated to dryness under vacuum to yield the desired product(formula (XC)), which was taken to the next step without furtherpurification.

Pathway Z providesN-(tert-butylcarbamoyl)-2-((4′-methoxy-[1,1′-biphenyl]-3-yeoxy)-5-(trifluoromethyl)benzenesulfonamide, formula (XCI).

A microwave tube was charged with the sulfonylurea (Formula (XC), 250mg, 0.7 mmol), the methoxy biphenyl (182 mg, 0.8 mmol), Cs2CO3 (456 mg,1.39 mmol), CuI (7 mg, 0.036 mmol) and dioxane (1.5 mL). The mixture washeated at 120° C. for 2 hours under microwave irradiation. After coolingto room temperature, the reaction mixture was diluted with EtOAc thenwater. The reaction was acidified using 1 N HCl to pH 1. The aqueousphase was extracted with EtOAc (×2) and the combined organic phases weredried over MgSO4, filtered and evaporated to dryness. The crude productwas dissolved in DMSO (1.5 mL) and then purified by preparative HPLC toyield the desired product as an off white solid (Formula (XCI), 39.1 mg,11%).

N-(tert-butylcarbamoyl)-2-chloro-5-fluorobenzenesulfonamide, formula(XCIII), is made from (XCII) in Pathway AA.

A solution of 2-chloro-5-fluorobenzenesulfonamide (Formula (XCII), 350mg, 1.69 mmol) in acetone (4 mL) was treated with a solution ofpotassium hydroxide (95 mg, 1.69 mmol) in H₂O (600 μL). The reaction wasstirred at room temperature for 15 minutes after which time the solventwas removed under vacuum. The residue was taken up in DMF (4 mL),treated with tert-butylisocyanate (390 μL, 3.39 mmol) and stirredovernight at room temperature. The DMF was removed under high vacuum andthe residue was suspended in H₂O (5 mL) before addition of 6 N NaOH (5mL). The reaction was stirred and sonicated, then acidified using 12 NHCl to pH 1. The resulting white solid was collected by filtration,washed with 2 N HCl and dried under suction on a sinter. The solid wasdissolved in EtOAc (50 mL) and the combined organic phases were driedover MgSO₄, filtered and evaporated to dryness to yield the desiredproduct (Formula (XCIII), 520 mg, 100% yield).

N-(tert-butylcarbamoyl)-5-fluoro-2-((4′-methoxy-[1,1′-biphenyl]-3-yl)oxy)benzene-sulfonamide,formula (XCIV), is prepared from (XCIII) in Pathway AB.

A microwave tube was charged with the sulfonylurea represented byformula (XCIII), 171 mg, 0.55 mmol), the methoxy biphenyl (6, 145 mg,0.72 mmol), Cs₂CO₃ (360 mg, 1.1 mmol), CuI (6 mg, 0.031 mmol) anddioxane (1.5 mL). The mixture was heated at 120° C. for 2 hours undermicrowave irradiation. After returning to room temperature, the reactionmixture was diluted with EtOAc and water. The aqueous phase wasacidified using 1 N HCl to pH 1 and then separated, re-extracting withEtOAc (×2). The combined organic phases were dried over MgSO₄, filteredand evaporated to dryness under vacuum. The crude product was dissolvedin DMSO (1.5 mL) and then purified by preparative HPLC to yield thedesired product (Formula (XCIV), 3 mg, 9%).

Pathway AC shows preparation of2-chloro-5-(methylsulfonyl)benzenesulfonamide, Formula (XCVI) from(XCV).

To chlorosulphonic acid (25 mL) cooled on an ice-salt bath,4-chloro-1-methylsulphonylbenzene (Formula (XCV), 5 g, 26.2 mmol) wascarefully added and the mixture was heated to reflux (160° C.) for 1hour. The reaction was cooled to room temperature and then SOCl₂ (1.5mL) was added. The mixture was heated to reflux for a further 2 hoursand then allowed to cool to room temperature before pouring onto iceunder stirring. A precipitate was collected by filtration and washedwith cold water. The solid was then added to a solution of NH₄OH (150mL, 10% w/v) and stirred overnight at room temperature. The reaction wasacidified to pH 4-5 using concentrated HCl and the resulting solid wascollected and dried. The crude product was dissolved with the aid ofsonication in EtOAc (100 mL) and then dried over magnesium sulfate andfiltered before concentrating to dryness under vacuum to yield thedesired product as an off white solid (Formula (XCVI), 360 mg, 5.1%).The 2-chloro-5-(methylsulfonyl)benzenesulfonamide (XCVI) was taken on tothe next step without further purification.

In Pathway AD, N-(tert-butylcarbamoyl)-2-chloro-5-(methylsulfonyl)benzene-sulfonamide, Formula (XCVIII) is made from (XCVII).

Sodium hydride (60% in oil dispersion, 60 mg, 1.46 mmol) was added to asolution of 2-chloro-5-(methylsulfonyl) benzenesulfonamide (33, 360 mg,1.33 mmol) in DMF (10 mL) at room temperature. The mixture was stirredat room temperature for 15 minutes before tert-butylisocyanate (212 μL,1.862 mmol) was added. The resulting mixture was stirred overnight atroom temperature. The reaction was quenched with water and then the DMFwas removed under high vacuum. The residue was diluted with EtOAc andH₂O, then acidified using 1 N HCl to pH 1. The product was extractedwith EtOAc and the combined organic phases were washed with brine, driedover MgSO₄, filtered and evaporated to dryness. The crude product wassonicated for 10 minutes with DCM/MeOH (1:1, 40 mL), then filtered toyield as a white solid (Formula (XCVIII), 0.3 g, 56%) which was used in,e.g., Pathway AE, without further purification.

Pathway AE synthesizesN-(tert-butylcarbamoyl)-2-((4′-methoxy-[1,1′-biphenyl]-3-yl)oxy)-5-(methylsulfonyl)benzenesulfonamide, Formula (XCIX) from (XCVIII).

An aqueous solution of NaOH (10% w/v, 80 mg; 2.0 mmol) was added to asolution of the phenol (6, 366 mg; 1.82 mmol) in acetone (10 mL). Thesolvents were removed under vacuum to afford the sodium salt, which wasadded to a solution of sulfonamide (34, 135 mg g; 0.367 mmol) inacetonitrile (20 mL). The mixture was heated to reflux and thenpotassium carbonate (35 mg, 0.257 mmol) was added, maintaining thistemperature for 18 hours. The solvents were removed under vacuum and theresidue was re-dissolved in DMSO (1.5 mL) and then purified bypreparative HPLC to yield an off-white solid (Formula (XCIX), 57 mg,29%).

The synthesis of modified nitriles is shown.

In Pathway AF,5-bromo-2-((4′-methoxy-[1,1′-biphenyl]-3-yl)oxy)-4-methyl-benzene-sulfonamide,formula (CI), is synthesized from Formula (C).

A 10% w/v aqueous solution of NaOH (10.23 mmol) was added to a solutionof phenol (1.12 g, 5.58 mmol) in acetone (50 mL). The reaction wasevaporated under reduced pressure to afford the sodium salt. The5-bromo-2 fluoro-4-methylbenzene sulfonamide (Formula (C), 0.5 g, 1.86mmol) was dissolved in acetonitrile (20 mL) and added to the sodiumsalt, dissolved in acetonitrile (30 mL). The resulting reaction mixturewas heated to reflux. Potassium carbonate (180 mg, 1.302 mmol) was addedafter 30 minutes and the reaction left to reflux for 18 hours, afterwhich time LC-MS analysis showed starting material only. The reactionmixture was then heated in the microwave for 4 hours at 140° C., afterwhich time LC-MS analysis showed approximately 25% conversion. Theacetonitrile was removed under reduced pressure and the residue wastaken up in ethyl acetate/H₂O. The aqueous layer was acidified usingconcentrated HCl (pH=1) and the organics were separated and the aqueousre-extracted with ethyl acetate (×2). The combined organics were driedand evaporated to give a brown oil (˜2 g). The oil was re-dissolved inDCM and loaded onto 100 g Biotage silica cartridge and purified byBiotage chromatography (eluting with iso-hexane/ethyl acetate, gradient20-80%). The fractions containing product were combined and evaporatedto give an orange oil (˜0.6 g). LC-MS analysis showed 77.4% purity, andtherefore, the oil was re-purified by loading onto 50 g Biotage silicacartridge and purified by Biotage chromatography (eluting withiso-hexane/ethyl acetate, gradient 0-50%) and dried to give the finalproduct (Formula (CI), 361 mg).

In Pathway AG,5-cyano-2-((4′-methoxy-[1,1′-biphenyl]-3-yl)oxy)-4-methylbenzenesulfonamide,Formula (CII), is prepared.

The sulfonamide (Formula (CI), 480 mg, 1.071 mmol) was dissolved in DMF(4 mL) and Zn(CN)₂ (189 mg, 1.606 mmol) was added. The reaction mixturewas flushed with nitrogen before the addition of Pd(PPh₃)₄ (124 mg,0.107 mmol). The vial was sealed and heated to 80° C. for 72 hours. Thesolid was filtered off and the DMF removed under high vacuum. Theresulting crude solid was taken up in DCM and H₂O and the organicsseparated, dried and evaporated to give a pale yellow oil (˜550 mg). Theoil was dissolved in DCM and loaded onto 50 g Biotage silica cartridgeand purified using Biotage chromatography (eluting with iso-hexane/ethylacetate, gradient 20-75%) and the product containing fractions wereconcentrated to dryness under vacuum to give an off white solid (Formula(CII), 175 mg, 41.4%).

Pathway AH producesN-(tert-butylcarbamoyl)-5-cyano-2-((4′-methoxy-[1,1′-biphenyl]-3-yl)oxy)-4-methylbenzenesulfonamide, Formula (LVIII), from (CII).

A solution of the sulfonamide (Formula (CII), 175 mg, 0.444 mmol) inacetone (2 mL) was treated with a solution of KOH (24.9 mg, 0.444 mmol)in H₂O (100 μL). The reaction was stirred at room temperature for 30minutes. The solvent was removed under high vacuum and the resultingresidue was dissolved in DMF (2 mL). tert-Butylisocyanate (101 μL, 0.888mmol) was added and the reaction was stirred for 18 hours at roomtemperature. The reaction mixture was evaporated to dryness under highvacuum and the residue re-dissolved in mixture of MeOH and DCM andloaded on to silica. The crude product was purified by Biotagechromatography on a 50 g Biotage Silica cartridge (elution withiso-hexane/ethyl acetate, gradient 0-75%), then triturated with diethylether/iso-hexane and dried under vacuum to give as a white solid(Formula (LVIII), 131 mg, 60%).

In Pathway AI,5-bromo-2-((4′-methoxy-[1,1′-biphenyl]-3-yl)oxy)pyridine-3-sulfonamide,Formula (CIV), is made.

A solution of 5-bromo-2-chloropyridine-3-sulfonamide (Formula (CIII), 1g, 3.63 mmol) and the methoxy biphenol (1.45 g, 7.26 mmol) inacetonitrile (40 mL) was heated at reflux overnight in the presence ofK₂CO₃ (1.03 g, 7.260 mmol). LC-MS showed ˜40% conversion. The reactionmixture was then heated to 140° C. for 1 hour, after which time LC-MSshowed complete conversion. The solvents were removed under vacuum andthe residue was diluted with water, and then extracted with DCM (50 mL).The organic phases were combined, dried over MgSO₄ and then concentratedto dryness directly onto silica. The crude product was purified byBiotage chromatography using a 100 g Biotage silica cartridge (elutingwith iso-hexane/EtOAc, gradient 0 to 50%) and the product containingfractions were concentrated to dryness under vacuum to give as a whitesolid (Formula (CIV), 0.92 g, 58%) which was used directly in the nextstep without further purification.

Using Pathway AJ, (CV) as a reactant yields5-cyano-2-((4′-methoxy[1,1′-biphenyl]-3-yl)oxy)pyridine-3-sulfonamide,Formula (CVI).

The pyridine sulfonamide (Formula (CV), 250 mg, 0.575 mmol), Zn(CN)₂(101 mg, 0.862 mmol), Pd(PPh₃)₄ (66 mg, 0.0575 mmol) and DMF (3 mL) werecharged to a stem tube. The mixture was de-oxygenated by purging withnitrogen and then sealed under nitrogen. The reaction was heated to 80°C. for 72 hours. The solvents were removed under vacuum, loadingdirectly onto silica before purification by Biotage chromatography (50 gcartridge, eluting with DCM/MeOH gradient 0-5%). The product containingfractions were concentrated to dryness under vacuum to give a solid thatwas triturated with diethyl ether (4 mL), filtered and then dried toprovide as a white powder (Formula (CVI), 160 mg, 73%).

To prepareN-(tert-butylcarbamoyl)-5-cyano-2-((4′-methoxy-[1,1′-biphenyl]-3-yl)oxy)benzene-sulfonamide,Formula (LIX), from (CVI), Pathway AK is used.

KOH (33 mg, 0.5879 mmol) in water (0.4 mL) was added to a solution ofthe pyridine sulphonamide (Formula (CVI), 160 mg, 0.412 mmol) in acetone(8 mL). The mixture was stirred for 2 minutes and then concentrated todryness under vacuum. The residue was dissolved in DMF (1 mL) before theaddition of tert-butylisocyanate (96 μL, 0.840 mmol) and stirred for 3hours. The reaction was concentrated to dryness. The crude product wasre-dissolved in a mixture of DCM/MeOH and then loaded onto silica. Thecrude product was purified by Biotage chromatography (50 g cartridge,eluting with DCM/MeOH, gradient 0-5%). The product fractions werecombined and concentrated to dryness to give as an off-white solid(Formula (LIX), 149 mg, 74%).

Synthesis of a pyridyl compound is described.

In Pathway AL,4-((4′-methoxy-[1,1′-biphenyl]-3-yl)oxy)pyridine-3-sulfonamide, formula(CVIII) is made.

For pathway AL, an aqueous solution of NaOH (330 mg, 8.25 mmol, 10%w/v,) was added to a solution of the 4′-methoxy[1,1′-biphenyl]-3-ol (1.5g, 7.5 mmol) in acetone (45 mL). The solvents were removed byevaporation to afford the sodium salt which was added to a solution ofthe 4-chloropyridine-3-sulfonamide (Formula (CVII), 723 mg, 1.5 mmol) inMeCN (45 mL). The reaction mixture was heated under reflux for 1 hour.The reaction was cooled, K₂CO₃ (364 mg, 2.63 mmol) was added and thereaction heated to reflux for 72 hours. A solid product was obtainedwhen DCM (50 mL) and H₂O (30 mL) were added. The crude product wascollected by filtration, washed with aqueous 10% K₂CO₃ (4×10 mL) toyield the target compound (Formula (CVIII)) which may be taken throughto Pathway AM without further purification.

Pathway AM shows the preparation ofN-(tert-butylcarbamoyl)-4-((4′-methoxy-[1,1′-biphenyl]-3-yl)oxy)pyridine-3-sulfonamide,represented by formula (LVII).

The pyridine sulfonamide (Formula (CVIII), 150 mg, 0.42 mmol) wasdissolved in acetone (2 mL) before adding a solution of KOH (33.3 mg,0.59 mmol) in H₂O (0.6 mL) and was then stirred for 20 minutes. Thesolvent was removed under vacuum and the residue was re-dissolved in DMF(2 mL). tert-Butylisocyanate (135 μL, 0.84 mmol) was added and thereaction mixture was stirred overnight at room temperature. The reactionmixture was evaporated to dryness under reduced pressure. The residuewas dissolved in DMSO (˜1.5 mL) and purified by preparative HPLC toyield the title compound as a white solid (Formula (LVII), 37 mg, 40%).

The N-oxide of Formula (LVII) can be synthesized according to PathwayAN, i.e., producing3-(N-(tert-butylcarbamoyl)sulfamoyl)-4-((4′-methoxy-[1,1′-biphenyl]-3-yl)oxy)pyridine1-oxide, Formula (LX).

In Pathway AN, tert-butylperoxide (12 μL, 0.0594 mmol) was added to asolution of pyridyl (Formula (LVII), 16 mg, 0.0396 mmol) in DCM (1 mL)and the reaction was stirred for 18 hours. LC-MS analysis showed noconversion. A further aliquot of tert-butylperoxide (24 μL, 0.119 mmol)was added and after a further 4 hours of stirring there was still noreaction, as confirmed by LC-MS. m-CPBA (15 mg, 0.0869 mmol) was addedand the reaction was stirred for 18 hours. LC-MS analysis confirmedcomplete conversion to the desired product. The solvents were removedunder vacuum and the crude product was re-dissolved in DMF (1.5 mL) andthen purified by preparative HPLC to give the desired product (FormulaLX, 6.8 mg, 36%).

The foregoing pathways are illustrative of possible ways to preparecompounds of the invention and are not limiting. Using pathways such asthose described above, compounds of the invention can be synthesized,such as those described by the formulas (LII), (LXXV), (XCI), (LXII),(LXXIV), (LXIII), (LXI), (XCIV), (LXX), (LXXVI), (LXXXV), (LXXXVII),(LXXVIII), (LXXX), (LXXXI), (LXXXII), (LXXXIII), (LXIV), (LXV), (LXVI),(LXVII), (LXXIX), (LXXXVIII), (LXXXVI), (LXXXIV), (CIX), (XCIX),(LXXVII), (LXVIII), (CX), (LVII), (LVIII), (LIX), and (LX).

Compounds of the invention can be in a pharmaceutically acceptable saltform or as the free base. Suitable routes of administration includeoral, buccal, topical (including trans-dermal), injection, intravenous,nasal, pulmonary, and with or on an implantable medical device (e.g.,stent or drug-eluting stent or balloon equivalents).

The effective dosage of each agent can readily be determined by askilled person, having regard to typical factors such as the age,weight, sex and clinical history of the patient. A typical dosage couldbe, for example, 1-1,000 mg/kg, preferably 5-500 mg/kg per day, or lessthan about 5 mg/kg, for example administered once per day, every otherday, every few days, once a week, once every two weeks, or once a month,or a limited number of times, such as just once, twice or three or moretimes.

A pharmaceutical composition containing each active ingredient may be ina form suitable for oral use, for example, as tablets, troches,lozenges, fast-melts, aqueous or oily suspensions, dispersible powdersor granules, emulsions, hard or soft capsules, or syrups or elixirs.Compositions intended for oral use may be prepared according to anymethod known in the art for the manufacture of pharmaceuticalcompositions and such compositions may contain one or more agentsselected from sweetening agents, flavoring agents, coloring agents andpreserving agents, in order to provide pharmaceutically elegant andpalatable preparations. Tablets contain the active ingredient inadmixture with non-toxic pharmaceutically acceptable excipients whichare suitable for the manufacture of tablets. These excipients may be forexample, inert diluents, such as calcium carbonate, sodium carbonate,lactose, calcium phosphate or sodium phosphate; granulating anddisintegrating agents, for example corn starch, or alginic acid; bindingagents, for example starch, gelatin or acacia, and lubricating agents,for example magnesium stearate, stearic acid or talc. The tablets may beuncoated or they may be coated by known techniques to delaydisintegration in the stomach and absorption lower down in thegastrointestinal tract and thereby provide a sustained action over alonger period. For example, a time delay material such as glycerylmonostearate or glyceryl distearate may be employed. They may also becoated by the techniques described in U.S. Pat. Nos. 4,256,108,4,166,452 and 4,265,874, to form osmotic therapeutic tablets for controlrelease. Preparation and administration of compounds is discussed inU.S. Pat. No. 6,214,841 and U.S. Pub. 2003/0232877, incorporate byreference herein in their entirety.

Formulations for oral use may also be presented as hard gelatin capsulesin which the active ingredient is mixed with an inert solid diluent, forexample calcium carbonate, calcium phosphate or kaolin, or as softgelatin capsules in which the active ingredient is mixed with water oran oil medium, for example peanut oil, liquid paraffin or olive oil.

An alternative oral formulation, where control of gastrointestinal tracthydrolysis of the compound is sought, can be achieved using acontrolled-release formulation, where a compound of the invention isencapsulated in an enteric coating.

Aqueous suspensions contain the active materials in admixture withexcipients suitable for the manufacture of aqueous suspensions. Suchexcipients are suspending agents, for example sodiumcarboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose,sodium alginate, polyvinyl-pyrrolidone, gum tragacanth and gum acacia;dispersing or wetting agents such as a naturally occurring phosphatide,for example lecithin, or condensation products of an alkylene oxide withfatty acids, for example polyoxyethylene stearate, or condensationproducts of ethylene oxide with long chain aliphatic alcohols, forexample heptadecaethyleneoxycetanol, or condensation products ofethylene oxide with partial esters derived from fatty acids and ahexitol such a polyoxyethylene with partial esters derived from fattyacids and hexitol anhydrides, for example polyoxyethylene sorbitanmonooleate. The aqueous suspensions may also contain one or morepreservatives, for example ethyl, or n-propyl p-hydroxybenzoate, one ormore coloring agents, one or more flavoring agents, and one or moresweetening agents, such as sucrose or saccharin.

Oily suspensions may be formulated by suspending the active ingredientin a vegetable oil, for example arachis oil, olive oil, sesame oil orcoconut oil, or in a mineral oil such as liquid paraffin. The oilysuspensions may contain a thickening agent, for example beeswax, hardparaffin or cetyl alcohol. Sweetening agents such as those set forthabove, and flavoring agents may be added to provide a palatable oralpreparation. These compositions may be preserved by the addition of ananti-oxidant such as ascorbic acid.

Dispersible powders and granules suitable for preparation of an aqueoussuspension by the addition of water provide the active ingredient inadmixture with a dispersing or wetting agent, suspending agent and oneor more preservatives. Suitable dispersing or wetting agents andsuspending agents are exemplified, for example sweetening, flavoring andcoloring agents, may also be present.

The pharmaceutical compositions of the invention may also be in the formof oil-in-water emulsions. The oily phase may be a vegetable oil, forexample olive oil or arachis oil, or a mineral oil, for example liquidparaffin or mixtures of these. Suitable emulsifying agents may benaturally-occurring gums, for example gum acacia or gum tragacanth,naturally occurring phosphatides, for example soya bean, lecithin, andesters or partial esters derived from fatty acids and hexitolanhydrides, for example sorbitan monooleate and condensation products ofthe said partial esters with ethylene oxide, for example polyoxyethylenesorbitan monooleate. The emulsions may also contain sweetening andflavoring agents.

Syrups and elixirs may be formulated with sweetening agents, for exampleglycerol, propylene glycol, sorbitol or sucrose. Such formulations mayalso contain a demulcent, a preservative and flavoring and coloringagents. The pharmaceutical compositions may be in the form of a sterileinjectable aqueous or oleaginous suspension. This suspension may beformulated according to the known art using those suitable dispersing orwetting agents and suspending agents which have been mentioned above.The sterile injectable preparation may also be in a sterile injectablesolution or suspension in a non-toxic parenterally acceptable diluent orsolvent, for example as a solution in 1,3-butanediol. Among theacceptable vehicles and solvents that may be employed are water,Ringer's solution and isotonic sodium chloride solution. In addition,sterile, fixed oils are conventionally employed as a solvent orsuspending medium. For this purpose any bland fixed oil may be employedincluding synthetic mono- or di-glycerides. In addition, fatty acidssuch as oleic acid find use in the preparation of injectables.

Each active agent, including the inventive compound, may also beadministered in the form of suppositories for rectal administration ofthe drug. These compositions can be prepared by mixing the drug with asuitable non-irritating excipient which is solid at ordinarytemperatures but liquid at the rectal temperature and will thereforemelt in the rectum to release the drug. Examples of such materials arecocoa butter and polyethylene glycols.

For topical use, creams, ointments, jellies, fast melt tablets,solutions or suspensions are suitable as are nebulized forms forpulmonary delivery. Topical application includes the use of mouth washesand gargles.

The invention further also generally relates to devices such asimplantable medical devices including an antithrombotic compound. Incertain aspects, the invention provides a stent (e.g., a drug-elutingstent) or balloon comprising a compound of the invention or a compoundof the invention along with other complementary drugs such as sirolimus,paclitaxel, tPA, urokinase etc. A device of the invention may be adrug-eluting aortic valve prosthesis or a drug-eluting mitral valveprosthesis. Accordingly, the invention provides administration of acompound of the invention via delivery from a stent, aortic valve, ormitral valve. In some embodiments, the invention provides a drug-elutingaortic valve or drug-eluting mitral valve.

In certain embodiments, the invention provides an implantable medicaldevice or balloon comprising a compound of the invention for use inpercutaneous cardiovascular intervention (PCI). A device of theinvention can be a stent or a balloon. The invention also providesmethods of using devices comprising antithrombotic compounds. Devicesand methods of the invention can provide a TP antagonist compound in astent (e.g., DES), balloon, implantable device, or surgical device or acompound of the invention along with other complementary drugs such astPA, urokinase etc. In a preferred embodiment, the compound has formula(X). Devices and antithrombotic compounds are discussed in U.S. Pat. No.7,947,302; U.S. Pat. No. 7,618,949; and U.S. Pub. 2006/0122143, thecontents of which are hereby incorporated by reference in theirentirety.

A stent according to the invention can comprise a mesh tube-likestructure, for example, to be used in conjunction with angioplasty topermanently hold open an artery at the narrowed site in the bloodvessel, allowing for unrestricted blood flow, or to support a weaknessor “aneurysm” in the blood vessel artery wall. Stents are discussed inU.S. Pat. No. 6,796,998; U.S. Pat. No. 6,352,552; U.S. Pub.2005/0015136; U.S. Pub. 2005/0010279; and U.S. Pub. 2007/0168015, thecontents of each of which are herein incorporated by reference in theirentirety.

Compounds of the invention, such as the compound having formula (X),provide coating agents for stents, drug-eluting stents (DESs),bifurcation stents, by-pass graft vessel stents, balloons, medicaldevices, or surgical devices used, for example, to treat stroke or otherthrombotic events. By antagonizing the TP receptor on platelets andmacrophages, these compounds will prevent platelet aggregation andsecretion at sites of local vessel damage and counteract theinflammatory effects of elevated levels of TXA₂ at sites of local vesseldamage. By antagonizing the TP on smooth muscle cells (SMCs), thecompounds will prevent TXA₂-induced SMC proliferation, neo-intimathickening and restenosis. Furthermore, as the TP also mediates theadverse actions of the isoprostane 8-iso-prostaglandin (PG)F_(2α),generated in abundance from arachidonic acid non-enzymatically from freeradicals in situations of oxidative stress/injury, including inischemia, compounds of the invention may also inhibit the undesirableactions of 8-iso-PGF_(2α) within the damaged blood vessel. Thecombination of these compounds with very low levels of sirolimus and/orpaclitaxel may be synergistic in further preventing restenosis while atthe same time in eliminating/reducing the adverse effects associatedwith local, high levels of sirolimus or paxlitaxol. The combination ofthese compounds along with clot lysing drugs such as tPA, urokinase orrelated type of drug can both lyse clots at sites of occlusion andprevent new thrombus formation, such as in the treatment ofatherothrombosis, ischemic or cerebral stroke etc. DESs are discussed inU.S. Pat. No. 7,135,038; U.S. Pat. No. 5,697,967; U.S. Pub.2011/0099785; U.S. Pub. 2010/0023115; and U.S. Pub. 2005/0043788, thecontents of each of which is herein incorporated by reference in theirentirety. Coating of stents is discussed in U.S. Pat. No. 7,833,544 andU.S. Pub. 2009/0062904, the contents of which are herein incorporated byreference in their entirety.

In certain embodiments, the invention provides TP antagonists with novelapplications as a coating or a component of a device either used aloneor in combination with very low levels of sirolimus and/or paxlitaxol.The release profile and timing of the release profile of both thecompound of the invention (e.g., formula (X)) along with eithersirolimus and/or paxlitaxol can be optimized to maximize theanti-thrombotic and anti-restenosis effects. This can result in theprevention of signaling by the elevated levels of TXA₂, and of theisoprostane 8-iso-PGF_(2α), found in vicinity of damaged blood vesselspost angioplasty and stenting. Prevention of this signaling prevents orreduces the impairment of the host immune response which arise due toelevated levels of TXA₂, and the isoprostane 8-iso-PGF_(2α), in thevicinity of damaged blood vessels post angioplasty and stenting.Compounds of the invention may further prevent restenosis, for example,by antagonizing TP on smooth muscle cells. Compounds of the inventioncould also be coated onto aortic or mitral valves which are used in TAVI(trans-catheter aortic valve intervention) to treat aortic stenosis.Such coating with the compounds onto aortic or mitral valves may preventthrombus or stroke occurrence after TAVI surgery.

The invention provide compounds which can be used as a coating on baremetal stents, interwoven stents, drug-eluting stents and balloons,bifurcation stents and by-pass graft stents, namely for use as: (a) ananti-restenosis agent, (b) an anti-thrombotic agent and (c) a prore-endothelialization agent. Compounds of the invention would bereleased from such coated medical devices used in the treatment ofvarious diseases of the vasculature including coronary arterial disease(CAD) and peripheral arterial disease (PAD) in a pre-defined mannerincluding zero order release, first order release and/or a combinationof initial burst release followed by controlled release over a definedtime period (e.g., 12 months). Compounds of the invention may beparticularly beneficial in Aspirin resistant patients (˜30% of thegeneral population) who are even more vulnerable to acute coronary stentthrombosis and who develop elevated levels of prostanoids such as TXA₂post stenting (Ruef & Kranzhofer, 2006, J Inter. Cardiol. Vol 19, pages507-509). Other applications of the new small molecule drug as a coatingon medical devices include applications on (a) bifurcation stents orby-pass graft lesion stents, (b) clot dissolvers on medical devices usedto treat stroke and further prevention of clot formation on medicaldevices for neurological applications, (c) as well as a coating oninferior vena cava filters (IVCFs) used to treat severe deep veinthrombosis (DVT) or pulmonary embolism (PE) in various types of patientsincluding those subject to various surgical interventions such asbariatric surgery, orthopedic surgery, trauma patients and diabeticpatients undergoing surgical intervention. Drug delivery from devices isdiscussed in U.S. Pat. No. 7,713,538; U.S. Pub. 2004/0213818 and U.S.Pub. 2009/0311299, incorporated by reference herein in their entirety.

As various compounds of the invention do not require liver metabolism toachieve an active therapeutic form, they provide the benefit ofimmediate therapeutic effect within the vasculature at the site ofrelease or immediate local environment of the coated medical device.This drug coating on medical devices has applications as prophylaxisand/or as therapeutic treatment.

INCORPORATION BY REFERENCE

References and citations to other documents, such as patents, patentapplications, patent publications, journals, books, papers, webcontents, have been made throughout this disclosure. All such documentsare hereby incorporated herein by reference in their entirety for allpurposes.

EQUIVALENTS

Various modifications of the invention and many further embodimentsthereof, in addition to those shown and described herein, will becomeapparent to those skilled in the art from the full contents of thisdocument, including references to the scientific and patent literaturecited herein. The subject matter herein contains important information,exemplification and guidance that can be adapted to the practice of thisinvention in its various embodiments and equivalents thereof.

EXAMPLES Example 1 Calcium Mobilization

The appropriate functional test for the evaluation of the agonisticand/or antagonistic potency of the compounds of the invention is thedetermination of calcium flux. Both TPα and TPβ are coupled to theG-protein Gαq. Therefore, stimulation of these receptors ultimatelyleads to a release of intracellular calcium ([Ca²⁺]_(i)) fromintracellular stores. Consequently, the determination of [Ca²⁺]_(i) fluxrepresents an appropriate functional test for the evaluation of theagonistic/antagonistic potency of compounds of the invention. Calciumcan be measured using a molecule characterized by the covalentcombination of a Ca²⁺ chelating group and a fluorophore group. The Ca²⁺binding properties of these indicators are formed by the presence of atetracarboxylic acid core as found for example in EGTA (ethylene glycolbis(2-aminoethyl) tetraacetic acid). Binding of Ca²⁺ produces awavelength shift in either the excitation or emission fluorescencespectra or a change in the emission intensity. Whereas the Ca²⁺ bindingto EGTA is pH dependent, recent dyes are designed from an EGTAderivative, BAPTA (1, 2-Bis(2-Aminophenoxy)ethane-N, N, N′,N′-Tetraacetic Acid). Loading of these dyes inside cells commonly usesesterified forms (acetoxymethyl ester), which are able to cross the cellmembranes and are subsequently hydrolyzed by esterases inside the cell.

Estimation of [Ca²⁺]_(i) flux is calculated from the fluorescence signal(F). For calibration, the maximal fluorescence (F_(max), Ca²⁺-saturatedform of the dye) as well as minimal fluorescence (F_(min), Ca²⁺-freeform of the dye) must be determined. These parameters are determinedusually in situ after the experiment, for example by subsequent additionto the mixture of a cell-disrupting agent that releases all Ca²⁺ such asTriton X100 and a potent Ca²⁺-chelating agent such as EGTA. Aftersubtraction of background fluorescence, [Ca²⁺]_(i) flux can becalculated for non-ratiometric indicators.

Intracellular [Ca²⁺]_(i) fluxes were measured using a fluorescence platereader following a modified protocol of Kassack et al., Quantitativecomparison of functional screening by measuring intracellular Ca²⁺ withradioligand binding at recombinant human dopamine receptors. AAPSPharmsci, 2002, 4(4); 102-111, in cell lines (e.g. HEK293 or other celltype) endogenously-expressing or over-expressing either TPα, TPβ or anyother receptor or protein to be screened.

By way of example, HEK 293 cells which have been grown for 3-4 days innormal growth media (minimum essential media containing 10% FBS and 2mmol/1 L-glutamine), under normal growth conditions (37° C., inhumidified 5% CO₂ atmosphere) are washed and harvested in KREBs-HEPESbuffer (118 mM NaCl, 4.7 mM KCl, 1.2 mM MgSO₄, 1.2 mM KH₂PO₄, 4.2 mMNaHCO₃, 11.7 mM D-glucose, 1.3 mM CaCl₂, 10 mM HEPES, pH 7.4). Cells arethen incubated with 3 μM Fluo-4 in KREBs-HEPES buffer containing 1%Pluoronic F-127, for 1 hr at 25° C. with agitation. Thereafter, cellsare washed in KREBs-HEPES buffer containing 0.5% bovine serum albuminand resuspended at a final concentration of 3×10⁵ cells/ml.Approximately, 5.4×10⁴ cells per well are plated in a 96-well plate andpre-incubated with test compounds for 10 min prior to measuring thefluorescence intensity at 520 nm for 25 seconds at 1 second intervals tomonitor baseline using the Fluoroskan Ascent. Agonist (e.g., 1 μMU46619) is injected into separate wells by the automatic pipettor andfluorescence intensity is monitored at 520 nm for 75 seconds at 1 secondintervals. Thereafter, Triton X100 and EGTA are added sequentially whereF_(max) refers to maximal fluorescence intensity measured afterpermeabilization of the cells with 2% Triton X100 and F_(min) refers tofluorescence intensity measured after addition of 1 mM EGTA. Changes inmobilization of intracellular [Ca²⁺] concentration are calculated asfollows:

Δ[Ca²⁺]_(i) (nM)=Kd×(F−F_(min))/(F_(max)−F)

where an equilibrium constant (Kd) of 345 nM is used for Fluo-4.

The dye Fluo-4 has its excitation peak at 480 nm, in the visiblespectra, which spare cells to be damaged by UV (340-360 nm) stimulationand reduces auto-fluorescence of cells. It is not necessary to determinethe precise [Ca²⁺]_(i), but rather variations in concentrations.

The method allows the detection of [Ca²⁺]_(i) mobilization uponstimulation by U46619 in human TP platelets. Similarly, the [Ca²⁺]_(i)mobilization in response to U46619 stimulation (1 μM) in the HEK293 celllines is assessed. Both TPα and TPβ transfected cells responded in acomparable fashion. The [Ca²⁺]_(i) mobilization in response to otheragonists in HEK 293 and other cell types either endogenously-expressingor over-expressing other receptors or proteins is assessed.

As reference compounds for screening assays, compounds 9h and 9ag,previously described by Dogne and Hanson et al., (Hanson, J. S., S.Rolin, et al. (2005). JPET 313(1):293-301; Hanson et al. (2006). J MedChem 49(12):3701-3709; Hanson et al. (2007). J Med Chem50(16):3928-3936), or SQ29,548, previously described by Ogletree, M. L.,Harris, D. N., Greenberg, R., et al. Pharmacological actions of SQ29,548, a novel selective thromboxane antagonist. J Pharmacol Exp Ther234 435-441 (1985), were used. SQ29,548 and compound 9ag is commerciallyavailable from Cayman (CAY10535) while compound 9h was synthesized basedon published methodology.

TABLE 2.1 Reference Compounds

SQ29,548

Compound 9h

Compoung 9agSelected reference compounds (e.g. SQ29,548, 9h or 9ag) and compounds ofthe invention were tested for their ability to inhibit [Ca²⁺]_(i)mobilization induced by U46619 (1 μM) in a concentration-dependentmanner Examples of calculated IC₅₀ values, defined as the concentrationable to inhibit 50% of [Ca²⁺]_(i) mobilization, obtained for certainreference or invention compounds when tested in HEK293 cells stablyoverexpressing TPα (HEK.TPα cells) or TPβ (HEK.TPβ cells) are given inTable 2.2. When such effects of the selected reference and compounds ofthe invention were tested for antagonism of agonist (U46619)-induced[Ca²⁺]_(i) mobilization by the TPα and TPβ isoforms, a selectivity ratiowas also determined as the IC₅₀ TPα/IC₅₀ TPβ. Results collected in thisevaluation are presented in Table 2.2.

TABLE 2.2 Effect of TP antagonists on U46619-induced calciummobilization in HEK.TPα & HEK.TPβ cell lines. IC₅₀ data forU46619-mediated [Ca²⁺]_(i) mobilization (nM) TPα:TPβ TP Antagonist TPαTPβ Selectivity Ratio Compound 1746 379 4.5 9ag Compound 9h 612 270 2.3XXXVIII 4006 1991 2 IX 11,620 1545 7.5 XLI 106 16.5 6.4 XLIII 13,0209325 1.4 X 119 7.33 16.2 XLVI 114 36.5 3 XLV 185.6 33.7 5.5 XII 89.8 861

Example 2 Ex Vivo Platelet Aggregation

The effects of selected compounds of the invention onagonist-(U46619)-induced platelet aggregation ex vivo was examined.

A modification of the turbidimetric method originally developed by Born& Cross (Born, G. V. and Cross, M. J., The Aggregation of BloodPlatelets, J Physiol, 1963, 168:178-95) is used. The principle is basedon the diffraction of the light by particles. When a light beam passesthrough a suspension of particles, it is diffracted, depending on thenumber and the size of the particles in suspension.

In the Born & Cross method, a light beam passes through a plateletsuspension and the quantity of light is measured by a detector placedafter the sample. Upon platelet aggregation, the size of plateletaggregates will increase while the total number of free platelets willdecrease. Consequently, less light will be diffracted and the detectorwill record an increase in light intensity. The aggregometer has beendeveloped based on these concepts. Variations in light transmissionrecorded by this device reflects the platelet physiology. When anagonist of platelet aggregation is added to a platelet suspension,platelets undergo activation and shape change. This step ischaracterized by an increase in platelet's apparent volume and thus adecrease of transmitted light. Subsequent platelet aggregation graduallyforms aggregates of increasing size. Transmitted light slightlyincreases until a plateau is reached. The aggregation of platelet can beconfirmed after the experiment by visual direct inspection of the testtube.

Preparation of platelet suspension is achieved by blood centrifugation.After the blood is withdrawn from healthy volunteers, it is centrifugedat 160 g for 10 minutes. The platelets rich plasma (PRP) isre-centrifuged at 160 g for 10 min to remove contaminating red and whiteblood cells. The supernatant which is collected contains the PRP. Theremaining blood is subsequently centrifuged at 900 g for 15 min in orderto retrieve plasma (platelets poor plasma, PPP). PRP is diluted with PPPto reach a final concentration of 150×10³ platelets/μl. PRP is keptwarmed at 37° C. in the aggregometer and the adequate dilution of drugto test is introduced in the sample. Platelet aggregation is inducedafter 10 minutes incubation.

Light transmission (T) is measured throughout all the experiment, whichis ended 8 minutes after induction of aggregation. Maximal lighttransmission (Tmax) is determined in the sample without drugs. Minimallight transmission (Tmin) is measured in PRP without inducer.

Percentage of platelet aggregation inhibition reflects the drug potencyand is given by the following equation:

%=100×(1−((T−Tmin)/(Tmax−Tmin)))

Results are expressed as IC₅₀, which is defined as the drugconcentration required to inhibit 50% of platelet aggregation. By way ofexample, the ability of XLI, X, XLVI, XLV and XII compared to thereference compounds is shown in Table 2.3.

Compounds XLI, X, XLVI, XLV and XII have improved efficacy over thereference compounds (see Table 2.3 for summary data) previouslyidentified by Hanson et al. (2007). J Med Chem 50(16):3928-3936).

TABLE 2.3 Effect of TP antagonists on U46619-induced human plateletaggregation ex vivo. IC₅₀ data for inhibition of U46619-induced plateletTP Antagonist aggregation (nM) SQ29,548 8.33 Compound 985 9ag Compound9h 513 XLI 230 X 4.71 XLVI 4.12 XLV 159 XII 129

The method of assessing platelet aggregation also allows evaluation ofthe effect of the compounds of the invention on platelet aggregationupon stimulation by other agonists, e.g., adenosine diphosphate (ADP)and thrombin. By way of example, the ability of XLI, X, XLVI, XLV andXII to affect ADP and thrombin-induced platelet aggregation of humanplatelets ex vivo and all compounds of the invention tested did notaffect ADP- or Thrombin-induced aggregation.

Example 3 Screening of Compounds

The effects of selected compounds of the invention onagonist-(U46619)-induced platelet aggregation ex vivo was examined.

Compounds listed in Table 2.4 were initially screened through calciummobilisation assays using HEK 293 cells over-expressing the thromboxane(TX)A₂ receptor, 13 isoform (TPβ), referred to as HEK.TPβ cells andthereafter, activity was confirmed in HEK.TPα cells over-expressing thea isoform (TPα). The screening involved examining the effect of thecompounds, used at 1 and 10 μM concentrations, on calcium mobilised inresponse to the TXA₂ mimetic U46619 (1 μM). The data was compared tocompound Formula (X) (i.e., TP20) and the reference TP antagonist BM573(1) where the results are shown in FIGS. 1A-1B and Table 2.5 (n≧3).Table 2.4 gives the names used in the study for the compounds by formulareference.

TABLE 2.4 Names in study Formula Name XXI TP1 XIV TP2 XV TP3 XVI TP4XVII TP5 XXIV TP6 XVIII TP7 XIX TP8 XXVI TP9 III TP10 VIII TP11 XXX TP12XXXII TP13 XXXIV TP14 XXXVI TP15 XXXVIII TP16 IX TP17 XLI TP18 XLIIITP19 X TP20 XLVI TP21 XLVII TP22 XXV TP23 XXVII TP24 XXVIII TP25 XXIXTP26 XXXI TP27 XXXIII TP29 XXXV TP30 XXXVII TP31 XXXIX TP32 XL TP33 XLIITP34 L TP35 LII TP36 XLIV TP37 XLV TP38 XX TP39 LIV TP40 LVI TP41 XLVIIITP42 XLIX TP43 LI TP44 LIII TP45 XII TP46 LV TP47 XI TP48 LII NTP1 LXXVNTP2 XCI NTP3 LXII NTP4 LXXIV NTP5 LXIII NTP6 LXI NTP7 XCIV NTP8 LXXNTP9 LXXVI NTP10 LXXXV NTP11 LXXXVII NTP12 LXXVIII NTP13 LXXX NTP14LXXXI NTP15 LXXXII NTP16 LXXXIII NTP17 LXIV NTP18 LXV NTP19 LXVI NTP20LXVII NTP21 LXXIX NTP22 LXXXVIII NTP23 LXXXVI NTP24 LXXXIV NTP25 CIXNTP26 XCIX NTP27 LXXVII NTP28 LXVIII NTP29 CX NTP30 LVII NTP31 LVIIINTP32 LIX NTP33 LX NTP 41 XXIII Cay10535

CONCLUSIONS

Using the definition of activity as an “Antagonist, when used at 1 μM,that leads to greater than 50% inhibition of TP (1 μM U46619)-inducedactivity (e.g. [Ca²⁺]_(i) mobilization)”, a number of compounds wereACTIVE in HEK.TPβ cells, including NTP3 (—CF₃), NTP4 (—C≡N), NTP27(—SO₂ME) and the halide variants NTP7 (—Br), NTP8 (—F) & NTP30 (—Cl).Hence, key findings of the SAR that resulted from the synthesis ofNTP1-NTP33 & NTP41 are presented here.

In terms of inhibition of TPα/TPβ-induced calcium mobilization inHEK.TPα/HEK.TPβ cell lines, the smaller nitro group replacements, suchas —C≡N, the halides (—Br, —Cl & —F), —CF₃ and —SO₂Me exhibited goodability to antagonise the TPα/TPβ-mediated calcium responses;

A number of other NTP compounds showed limited efficacy in the calciummobilisation assays in the HEK.TPα/HEK.TPβ cell lines, i.e., ability toinhibit TP-mediated calcium responses, while others showed no affect.Hence, it was possible to group the NTPs into Active and Inactivecompounds. With regard to the ACTIVE NTPs, it was also possible to rankthem; however, it remains that the smaller substituents are mosteffective;

NTP4 (—C≡N), when used at 0.1 μM, showed an ability to inhibitTP-mediated platelet aggregation (in response to the TP agonist U46619)in whole blood platelet aggregation assays.

Determination of IC₅₀ values of NTP4 in side-by side comparison in (1)the HEK.TPα/HEK.TPβ cell lines and (2) platelets confirmed that whileNTP4 is a potent TP antagonist in terms of its ability to inhibitTP-mediated responses.

While NTP4 (—C≡N) is the most active of the nitro replacementssynthesised, substitution of the cyanobenzene ring, as in NTP32 (-methylgroup) and NTP33 (pyridyl ring), to change the electrophilicity of thecyano group resulted in loss of activity compared to the cyano compoundNTP4 and to the key lead TP20.

(1) Calcium Mobilisation Assays: Screening of NTP Compounds in HEK.TPβ &HEK.TPα Cells

FIG. 1 shows the effect of the TP antagonist compounds of the inventionon U46619-mediated calcium mobilization in HEK.TPα and HEK.TPβ cells.HEK.TPβ (FIG. 1A) and HEK.TPα (FIG. 1B) cells, preloaded with Fluo-4,were incubated with the TP20 (Batch#4), BM573, NTP1-NTP33 and NTP 41where each antagonist was used at 1 & 10 μM, as indicated, prior tostimulation with 1 μM U46619. Data is presented as the mean (±S.E.M.)percentage of the agonist-induced response in vehicle-treated cells(Percentage of Control; %) and represents data from at least 3independent experiments were cells were treated in duplicate.

TABLE 2.5 Summary of Calcium Data from Screening Assays. Percentage ofControl (%) TP TPα TPβ Antagonist 1 μM 10 μM 1 μM 10 μM TP20 45.4 ± 4.0717.1 ± 2.46 12.6 ± 1.46 9.96 ± 1.70 BM573 48.5 ± 1.77 12.0 ± 0.76 23.8 ±0.68 9.90 ± 1.80 NTP1 77.8 ± 8.71 50.2 ± 6.39  101 ± 4.75  102 ± 4.15NTP2 85.0 ± 2.71 54.9 ± 3.32  102 ± 3.59 90.1 ± 2.78 NTP3 69.6 ± 5.3541.6 ± 5.45 46.0 ± 5.92 14.8 ± 2.44 NTP4 46.1 ± 3.87 19.9 ± 2.13 22.5 ±3.70 10.2 ± 0.95 NTP5 98.7 ± 9.29 61.7 ± 1.42  88.3 ± 5.27*  72.0 ±3.87* NTP6 88.6 ± 14.5 45.1 ± 5.75 94.4 ± 7.70 57.4 ± 6.86 NTP7 61.5 ±7.70 32.5 ± 3.95 49.0 ± 4.41 12.2 ± 1.93 NTP8 68.0 ± 5.05 49.9 ± 6.9159.4 ± 1.85 14.6 ± 2.72 NTP9 85.9 ± 9.13 70.4 ± 2.47 46.3 ± 7.33 12.2 ±1.03 NTP10 95.5 ± 4.25 69.8 ± 1.73 96.0 ± 0.94 54.7 ± 8.10 NTP11 73.1 ±5.28 75.4 ± 5.83 49.8 ± 1.86 20.7 ± 2.81 NTP12 99.7 ± 2.13 77.9 ± 2.6984.2 ± 7.51 34.4 ± 2.85 NTP13 93.8 ± 13.9 95.2 ± 9.57 74.0 ± 3.66 36.2 ±0.52 NTP14 83.5 ± 9.26 89.1 ± 9.10 86.4 ± 7.06 59.4 ± 7.67 NTP15 79.8 ±8.81 52.6 ± 8.42 87.6 ± 8.28 86.1 ± 5.64 NTP16  117 ± 10.2 96.3 ± 1.2483.0 ± 7.62 34.0 ± 3.88 NTP17 83.1 ± 4.85 59.5 ± 4.07 51.1 ± 1.13 13.3 ±5.91 NTP18 93.4 ± 6.17 73.6 ± 2.98 45.0 ± 4.34 22.6 ± 2.28 NTP19 97.6 ±8.60 99.4 ± 16.0 77.7 ± 3.24 64.5 ± 4.65 NTP20 72.4 ± 5.97 55.7 ± 5.8442.5 ± 2.32 18.5 ± 3.53 NTP21 78.3 ± 8.28 66.4 ± 4.95 51.0 ± 1.62 32.2 ±2.89 NTP22  101 ± 7.28 87.6 ± 11.3 85.1 ± 4.38 50.1 ± 4.06 NTP23 64.2 ±2.89 49.9 ± 7.61 48.4 ± 2.75 20.4 ± 1.94 NTP24 96.8 ± 3.94  107 ± 6.4887.7 ± 8.18 37.9 ± 2.61 NTP25 80.0 ± 7.15 65.5 ± 6.32 61.6 ± 1.93 14.8 ±2.03 NTP26  101 ± 4.30 73.7 ± 3.56 68.6 ± 3.30 41.0 ± 3.88 NTP27 81.1 ±10.2 68.4 ± 4.56 36.4 ± 3.80 16.3 ± 2.39 NTP28  108 ± 7.64 89.5 ± 10.3 110 ± 1.85 62.3 ± 4.30 NTP29  113 ± 8.15  105 ± 8.03  100 ± 4.69 94.6 ±3.58 NTP30 52.2 ± 3.90 23.3 ± 3.63 46.5 ± 5.86 9.31 ± 1.57 NTP31 77.3 ±8.72 52.7 ± 2.89 74.8 ± 5.49 27.7 ± 4.21 NTP32 80.3 ± 4.21 69.3 ± 2.0793.6 ± 4.06 46.2 ± 4.83 NTP33  103 ± 6.25 82.4 ± 5.86 75.6 ± 6.46 34.5 ±1.56 NTP41 82.6 ± 3.41 52.8 ± 8.03 72.2 ± 5.66 18.8 ± 1.77

Note that reference compound BM573 is shown by Formula (CXI). Also seeRolin, S., Dogne, J. M., Michaux, C., Delarge, J., and Masereel, B.(2001) Prostaglandins Leukot Essent Fatty Acids 65, 67-72.

TP20 has been identified as a key lead compound. Consistent with this,at 1 & 10 μM concentrations, TP20 potently inhibited U46619-mediatedcalcium mobilization in HEK.TPβ cells, where responses were reduced byapprox. 90%. Likewise, the reference compound BM573, potently inhibitedU46619-mediated responses at the concentrations tested. Of the NTPcompounds NTP1-NTP33 & NTP41, a number showed good antagonist activity,including NTP3 and NTP4.

Active compounds that showed ≧50% inhibition of U46619-mediatedresponses in HEK.TPβ cells were subject to further characterizationthrough both calcium and platelet aggregation assays. These compoundsinclude NTP3 (—CF3), NTP4 (—C≡N), NTP7 (—Br), NTP8 (—F), NTP9 (—COMe),NTP11 (amide), NTP17 (amide), NTP18 (C-linked palladium chemistry),NTP20 (C-linked palladium chemistry), NTP21 (C-linked palladiumchemistry), NTP23 (amide), NTP25 (amide) and NTP27 (—SO2Me).

Initially, the ability of the selected ACTIVE compounds listed above toinhibit U46619-mediated calcium responses in HEK.TPβ cells was examined,where the concentration were reduced to 0.5 μM and 1 μM, such that thecompounds could be ranked in terms of activity.

FIG. 2 shows the effect of the TP antagonists on U46619-mediated calciummobilization in HEK.TPβ cells. HEK.TPβ cells, preloaded with Fluo-4,were incubated with the TP20 and the selected ACTIVE NTP compounds,where each antagonist was used at 0.5 or 1 μM, as indicated, prior tostimulation with 1 μM U46619. Data is presented as the mean (±S.E.M.)percentage of the agonist-induced response in vehicle-treated cells(Percentage of Control; %) and represents data from 4 independentexperiments were cells were treated in duplicate.

The selected NTP compounds were ranked based on the data from thecalcium responses in HEK.TPβ cells where cells were treated with 0.5 μMof the compound. The compounds, in order in decreasing potency, includeNTP4>NTP7>NTP3>NTP27>NTP8>NTP20>NTP23>NTP9>NTP11>NTP17>NTP18>NTP21>NTP25.

It is noteworthy that the smaller nitro group replacements, such as —Br,—CF3, —SO2Me and —F exhibit the greatest ability to antagonize theTPβ-mediated calcium responses. NTP4 exhibited greater than 50%inhibition of U46619-mediated responses when used at 0.5 μM, similar tothe previously identified TP20 and TP46. Hence, IC50 value forinhibition of U46619-mediated responses was determined in side-by-sidecomparison with TP20.

Example 4 Determination of IC50 Values for Inhibition of TP-Mediated[Ca2+]i Mobilization

Determination of IC50 values for NTP4 and TP20, in side-by-sidecomparison, has been performed in both HEK.TPα and HEK.TPβ cells. Table2.6 shows the results, where n=5 and n=6 for HEK.TPα and HEK.TPβ,respectively.

TABLE 2.6 IC₅₀ values for inhibition of U46619-mediated calciummobilization in HEK.TPα and HEK.TPβ cells. IC₅₀ values for inhibition ofU46619-mediated [Ca²⁺]_(i) (nM) TP Antagonist TPα TPβ TP20 (—NO₂) 240 ±29.8 9.61 ± 1.46 NTP4 (—C≡N) 593 ± 83.6 60.4 ± 8.00 NTP4 and TP 20 arepotent compounds.

Example 5 (2) Ex Vivo Platelet Aggregation Assays

(A) Screening of ACTIVE NTP Antagonists: Whole Blood Aggregation Assays

In order to evaluate the NTP compounds in a second independent assay,the effect of the ACTIVE NTP compounds (i.e., those compounds, when usedat 1 μM, that exhibited ≧50% inhibition of TP (1 μM U46619)-inducedactivity in the initial screening calcium mobilization assays) onU46619-mediated platelet aggregation assays was examined From anefficacy point of view, this is an important assay and, physiologically,relevant with respect to the therapeutic target.

Initially, the Sysmex haematological analyzer was used to examine theeffect of the TP antagonists at a single concentration (0.1 μM) onU46619 (1 μM)-mediated platelet aggregation in whole blood.

FIG. 3 illustrates effects of the TP antagonist compounds onU46619-mediated platelet aggregation. Blood was taken form healthyvolunteer by venupuncture into syringes containing 3.8% sodium citrate,10 μM Indomethacin, such that the ratio of anticoagulant:blood was 1:9.The blood was aliquoted and incubated for 10 min with TP20 and selectedNTP compounds, as indicated, where the antagonist were used at 0.1 μMprior to stimulation with 1 μM U46619 for 3 min. The blood was fixedwith formaldehyde and platelet numbers counted using the Sysmexhaematological analyzer. Data is presented as the mean percentage ofcontrol or non-treated blood sample (Percentage of Control; %) andrepresent data from 3 independent experiments were samples were treatedin duplicate.

Consistent with previous data, the identified lead compound TP20, at 0.1μM, almost completely inhibited the reduction in platelet numbers causedby U46619-mediated platelet aggregation. NTP4 (0.1 μM) in some casesconsistently inhibited the U46619-mediated reduction in platelet numberby approx. 50%.

(B) Determination of IC50 Values for Inhibition of TP-Mediated PlateletAggregation

The effect of NTP4 and the previously identified lead TP antagonist,TP20, on U46619-mediated platelet aggregation in side-by-sidecomparisons was performed in platelet rich plasma (PRP) using the PAP-8Eplatelet aggregometer.

Table 2.7 shows the effect of TP Antagonists on U46619-mediated plateletaggregation and gives a summary of IC50 values for inhibition ofU46619-mediated platelet aggregation.

TABLE 2.7 Effect of TP Antagonists on U46619-Mediated PlateletAggregation: Summary of IC₅₀ Values for Inhibition of U46619-MediatedPlatelet Aggregation. IC₅₀ Value for Inhibition of U46619- MediatedPlatelet Aggregation TP Antagonist (Mean ± S.E.M.; nM) TP20 (Batch #4)4.62 ± 0.72 NTP4 (Batch #2) 40.3 ± 7.08

Note figures are based on data from ≧6 independent experiments.

FIG. 4A-4C show the effect of TP20 & NTP4 on U46619-mediated plateletaggregation. PRP was prepared from blood taken from healthy volunteersinto syringes containing 3.8% sodium citrate and 10 μM indomethacin suchthat the final ratio of anticoagulant to blood was 1:9. Aliquots of PRP(300 μl) were pre-incubated for 10 min with the TP antagonists, TP20 andNTP4, where 2-fold serial dilutions from 1 μM were prepared for each,prior to stimulating platelets with 1 μM U46619, incubated at 37° C.,with stirring. FIG. 4A and FIG. 4B: Representative dose-responseplatelet aggregation profiles for TP20 (FIG. 4A) and NTP4 (FIG. 4B),where data is presented as Percentage Aggregation, as determined bychanges in light transmission using the PAP-8E Platelet AggregationProfiler as a function of time. FIG. 4C: The dose-response curves forplatelet aggregation are presented as the mean (±S.E.M.) maximumPercentage Aggregation as a function of the log of the TP antagonistconcentration. Data presented is representative of ≧6 independentexperiments.

In side-by-side dose-response assays, TP20 is a potent TP antagonistwith IC50=4.62±0.72 nM (n=7) for inhibition of U46619-mediated plateletaggregation. NTP4 is approx. ten-fold less potent than TP20 withIC50=41.5±7.69 nM (n=6) for inhibition of U46619-mediated plateletaggregation.

1-32. (canceled)
 33. A compound of formula (XLI):

or a pharmaceutically acceptable salt thereof.
 34. A compound of formula(X):

or a pharmaceutically acceptable salt thereof.
 35. A compound of formula(XLVI):

or a pharmaceutically acceptable salt thereof.
 36. A compound of formula(XLV):

or a pharmaceutically acceptable salt thereof.
 37. A compound of formula(LXII):

or a pharmaceutically acceptable salt thereof.